<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001460" GROUP_ID="MUSKEL" ID="115399082413081337" MERGED_FROM="" MODIFIED="2011-09-06 12:22:12 -0400" MODIFIED_BY="Jordi Pardo Pardo" NOTES="&lt;p&gt;Short title (no longer in use): Penicillamine for rheumatoid arthritis&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-09-06 12:22:12 -0400" NOTES_MODIFIED_BY="Jordi Pardo Pardo" REVIEW_NO="C064-R" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2011-09-06 12:19:08 -0400" MODIFIED_BY="Jordi Pardo Pardo">
<TITLE>Penicillamine for treating rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Internal Medicine</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-09-06 12:19:08 -0400" MODIFIED_BY="Jordi Pardo Pardo">
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Internal Medicine</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9254" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Elaine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Belseck</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ebelseck@cha.ab.ca</EMAIL_1>
<EMAIL_2>ebelseck@cha.ab.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>2C3.67 Walter C Mackenzie</ADDRESS_1>
<ADDRESS_2/>
<CITY>Alberta</CITY>
<ZIP>T6G 2R7</ZIP>
<REGION/>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 492 1078</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407 8538</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5452" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Carol</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Spooner</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>spoonerc@telus.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Emergency Medicine</DEPARTMENT>
<ORGANISATION>1G1.52 Walter Mackenzie Health Centre</ORGANISATION>
<ADDRESS_1>8440 - 112 ST</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edmonton</CITY>
<ZIP>T6G 2B7</ZIP>
<REGION>Alberta</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 407-7576</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407-3314</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-07 23:09:58 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="8" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="8" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-07 23:10:21 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-07 23:10:21 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSG ID: C064-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-07 23:11:16 -0500" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Alberta Hospitals Foundation</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Arthritis Society</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Alberta Heritage Foundation for Medical Research</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-09-06 12:22:12 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-09-06 12:22:12 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-09-06 12:20:57 -0400" MODIFIED_BY="[Empty name]">Penicillamine for treating rheumatoid arthritis</TITLE>
<SUMMARY_BODY MODIFIED="2011-09-06 12:22:12 -0400" MODIFIED_BY="[Empty name]">
<P>Penicillamine is a penicillin derived compound. Studies showed that this could be used to treat rheumatoid arthritis originally in 1950. It was frequently used in the past, but its use has declined with the increasing use of other disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate. The purpose of this summary was to find out if penicillamine is helpful in the treatment of rheumatoid arthritis.</P>
<P>Penicillamine was seen to be beneficial for all ranges of dosages for disease activity on tender joint pain, physician global assessment and sed rate. No major differences were observed between placebo and low dose penicillamine (&lt;500 mg/day). For higher dosages, patients on penicillamine were twice as likely to withdraw than those receiving placebo 500 to &lt;1000 mg/day. D-penicillamine appears be have a clinical and statistical benefit on the disease activity of patients with rheumatoid arthritis. Its benefit is similar to that of other such drugs, such as disease modifying anti-rheumatic drugs (DMARDs). More adverse reactions are seen in patients being treated with D-penicillamine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>D-penicillamine is a penicillin derived compound originally used to treat patients with rheumatoid arthritis (RA) in the 1950's. Although frequently used in the past, its use has declined with the increasing use of other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To estimate the short-term effects of D-penicillamine for the treatment of rheumatoid arthritis (RA).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register (issue 3, 2000) and Medline up to and including August 2000 and Embase from 1988-2000. We also carried out a handsearch of the reference lists of the trials retrieved from the electronic search.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized controlled trials and controlled clinical trials comparing D-penicillamine against placebo in patients with rheumatoid arthritis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The methodological quality of the trials was assessed independently by two reviewers (CS, EB) and checked by a third (MS) using a validated quality assessment tool (Jadad 1996). Rheumatoid arthritis outcome measures were extracted from the publications for the six-month endpoint and stratified according to D-penicillamine dosages: low (&lt;500mg/day), moderate (500 to &lt;1000mg/day) and high (1000 mg/day or greater). Data was abstracted by one reviewer and checked by a second (CS, MS). The pooled analysis was performed using the standardized mean difference for joint counts, pain and global assessments. The weighted mean difference was used for erythrocyte sedimentation rate (ESR). Toxicity was evaluated with pooled odds ratios for withdrawals and adverse reactions. A chi-square test was used to assess heterogeneity among trials. Fixed effects models were used throughout, since no statistical heterogeneity was found.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Six trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo. A statistically significant benefit was observed for D-penicillamine when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR. The standardized weighted mean differences between treatment and placebo in moderate doses were -0.51 [95% CI -0.88, -0.14] for tender joint counts, -0.56 (95% CI -0.87, -0.26) for pain and -0.97 (95% CI -1.25, -0.70) for global assessment. The difference for ESR was -10.6 mm/hr. Similar results were observed for the higher dose group. Total withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-07 23:56:51 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>D-penicillamine is a penicillin derived compound, originally used for the treatment of Wison's disease and cystinuria. In vitro studies showed that D-penicillamine could dissociate macroglobulins such as rheumatoid factor (RF). The drug was originally used to treat patients with rheumatoid arthritis (RA) in the 1950's. Since then, several clinical trials examining its efficacy have been published. Although frequently used in the past, its use has declined with the increasing use of other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the short-term efficacy and toxicity of d-penicillamine for the treatment of RA, by conducting a systematic review of randomized controlled trials (RCTs) and controlled clinical trials (CCTs) comparing d-penicillamine and placebo.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomized controlled trials and controlled clinical trials, with a minimum duration of 3 months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a diagnosis of RA (as stated in the publication).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Intervention group: d-penicillamine, minimum dosage 125 mg/day, oral administration<BR/>Control group: placebo</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Efficacy<BR/>All the outcome measures in OMERACT (Outcome Measures for Rheumatoid Arthritis Clinical Trials 1993) were included for potential analysis, although only some were consistently reported across trials.</P>
<P>OMERACT measures for efficacy include:<BR/>a) Number of tender joints per patient<BR/>b) Number of swollen joints per patient<BR/>c) Pain<BR/>d) Physician global assessment<BR/>e) Patient global assessment<BR/>f) Functional status<BR/>g) Acute phase reactants<BR/>h) Radiological damage</P>
<P>Withdrawals and dropouts - these were analyzed as:</P>
<P>a) Total number of withdrawals and dropouts<BR/>b) Number of withdrawals from lack of efficacy<BR/>c) Number of withdrawals due to adverse reactions<BR/>d) Number of withdrawals due to concurrent illness<BR/>e) Number of withdrawals due to system-specific adverse reactions (e.g. gastrointestinal, renal, etc.) </P>
<P>Adverse effects not causing withdrawal were analysed as system-specific adverse reactions:<BR/>a) Gastrointestinal <BR/>b) Mucosal / cutaneous <BR/>c) Renal <BR/>d) Liver<BR/>e) Haematological <BR/>f) Neurological (headache, dizziness, tingling)<BR/>g) Impaired / loss of taste<BR/>h) Miscellaneous adverse reactions</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register (issue 3, 2000) and Medline up to and including August 2000 and Embase from 1988-2000. We also carried out a handsearch of the reference lists of the trials retrieved from the electronic search.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data extracted from the publications included study characteristics and outcome measures of efficacy and toxicity. Data was extracted by one reviewer (CS) and checked by a second (MS). </P>
<P>Efficacy<BR/>The results on efficacy were analysed for the 6-month endpoint when these data were available. This endpoint was chosen because it was reported in most of the trials and was thought to be the minimum required time to adequately assess the efficacy of D-penicillamine. A 4-month duration trial (<LINK REF="STD-Mery-1976" TYPE="STUDY">Mery 1976</LINK>) was included in the review and the results pooled with the other studies. </P>
<P>To determine if the effect of d-penicillamine depended on dose, outcomes on efficacy, withdrawals and adverse reactions were analyzed into the following dose categories: 125 to less than 500 mg/day, 500 to less than 1000 mg/day, 1000 or more mg/day.</P>
<P>The analysis compares end of trial results. When the standard deviation for results was not available, we imputed the baseline standard deviation (SD) or an estimated value using the coefficient of variation (CV=SD/mean) from the other trials. In the case of ESR results this was 0.70. If trials reported means and ranges, the range was divided by three to estimate the SD. Trials that reported change from baseline scores with no SD were not combined with trials that reported end of trial results. When imputing a SD, we elected to be as conservative as possible. Sensitivity analyses were performed when possible. We thought these procedures would introduce less bias than excluding the trial altogether. </P>
<P>End-of-trial results were pooled as standardized weighted mean differences (SMD) for joint scores, pain, and global assessments. This was necessary because of the variation in the way outcome measures were scored and reported in each study (e.g. different number of tender joints, tender joint index). Trial results were entered into RevMan 3.1.1 using the same direction to enable the pooling of results where the lowest value was improvement and the highest value was worsening. Negative values in SMD indicate a benefit of the active drug over placebo. ESR results were pooled using a weighted mean difference (WMD). For the lower dose trial ESR results were reported as change scores (<LINK REF="STD-Williams-1983" TYPE="STUDY">Williams 1983</LINK>). Because no other trials were pooled in this comparison, results are shown in MetaView as reported in the paper (change scores).</P>
<P>Withdrawals and dropouts<BR/>Adverse reactions were generally reported as overall results at the end of the trial. We therefore pooled withdrawals and dropouts at the end of the study although in some cases follow-up exceeded six months. Toxicity was analysed using a pooled odds ratio for total withdrawals from adverse reactions and withdrawals for system-specific side effects.</P>
<P>Adverse reactions<BR/>Adverse reactions were analysed using a pooled odds ratio for system-specific reactions that may have necessitated a dose adjustment in treatment but not withdrawal from the trial.</P>
<P>The heterogeneity of the trials for each pooled analysis was estimated using a chi-square test. No significant heterogeneity was observed so fixed effects models were used throughout.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Six trials met the criteria for inclusion, five randomized trials (<LINK REF="STD-Andrews-1973" TYPE="STUDY">Andrews 1973</LINK>, <LINK REF="STD-Dixon-1975" TYPE="STUDY">Dixon 1975</LINK>, <LINK REF="STD-Mery-1976" TYPE="STUDY">Mery 1976</LINK>, <LINK REF="STD-Shiokawa-1977" TYPE="STUDY">Shiokawa 1977</LINK>, <LINK REF="STD-Williams-1983" TYPE="STUDY">Williams 1983</LINK>) and one controlled trial (<LINK REF="STD-Huskisson-1976" TYPE="STUDY">Huskisson 1976</LINK>). The duration of studies ranged from four months to one year; they were conducted in the UK (3), France (1), Japan (1), and the USA (1), all prior to 1983. </P>
<P>D-penicillamine was administered orally at doses ranging from 125 mg/day to 1500 mg/day. These were stratified as described previously: low dose &lt; 500 mg/day, (<LINK REF="STD-Williams-1983" TYPE="STUDY">Williams 1983</LINK>), moderate dose 500 to &lt; 1000 mg/day, (<LINK REF="STD-Dixon-1975" TYPE="STUDY">Dixon 1975</LINK>, <LINK REF="STD-Mery-1976" TYPE="STUDY">Mery 1976</LINK>, <LINK REF="STD-Shiokawa-1977" TYPE="STUDY">Shiokawa 1977</LINK>, <LINK REF="STD-Williams-1983" TYPE="STUDY">Williams 1983</LINK>), high dose 1000 or more mg/day (<LINK REF="STD-Andrews-1973" TYPE="STUDY">Andrews 1973</LINK>, <LINK REF="STD-Dixon-1975" TYPE="STUDY">Dixon 1975</LINK>, <LINK REF="STD-Huskisson-1976" TYPE="STUDY">Huskisson 1976</LINK>, <LINK REF="STD-Mery-1976" TYPE="STUDY">Mery 1976</LINK>). Cumulatively, 425 patients received d-penicillamine and 258 placebo at the start of these trials.</P>
<P>Trials reported varying numbers of the OMERACT outcome measures, therefore, different numbers of trials are included in each comparison. The most consistently reported measures were joint scores, pain and ESR. </P>
<P>Two studies analyzed the results on the basis of intention to treat. The other four only reported final data on patients who completed the trial.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methodological quality of the studies was assessed independently by two of the investigators (MS, EB) using a quality scale validated and published by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). This scale includes an assessment of randomization, double-blinding procedures and description of withdrawals. The possible range of scores is 0 (worst) to five (best). One study had a score of five, three studies a score of four, and one each a score of three and two (see table of included studies). Disagreements were resolved by consensus. Concealment of allocation was considered adequate in two studies, unclear in three, and inadequate in the sixth study.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Five of the six trials could be evaluated for efficacy by meta-analysis. Huskisson reported change scores with no measure of dispersion and no baseline data. Other trials reporting change scores also provided baseline data, which was used to compute end of trial results. Whenever possible these calculations were performed and included. The only efficacy measures adequately reported for pooling were tender joints (three RCTs), pain (three RCTs), physician global assessment (three RCTs) and ESR (three RCTs). Williams was the only study to evaluate a low dose. The results from this study are reported in the tables for comparison but, of course, could not be pooled. </P>
<P>The origins of imputed standard deviations are described in the Table of Included Studies in the Notes section.</P>
<P>In the four-pooled analyses of clinical benefits that were possible, D-penicillamine provided a statistically significant benefit. There were no significant differences in effect size among dosage groups and the suggestion of a dose trend was not evident in these few trials, though the lower dosage showed somewhat smaller effect size that the moderate and high group (only one trial was included in the lower dose range). There was an equal reduction in tender joint scores in the moderate and high dose strata corresponding to an effect size of -0.51 [95% CI -0.88, -0.14] and -0.51 [95% CI -0.93, -0.08], respectively. Pain scores were reduced by an effect size of a similar magnitude SMD -0.56 [95% CI -0.87, -0.26] and -0.65 [95% CI -0.97, -0.32] for moderate and high doses. A statistically significant reduction was also observed for ESR in moderate and high dose groups of -10.65mm [95% CI -20.89, -0.41] and -14.39mm [95% CI -23.21, -5.58] respectively. Three studies reported a global physician score but only two, Williams and Shiokawa, both studying moderate doses, could be pooled. In this analysis d-penicillamine was judged to be superior to placebo with an effect size of -0.97 [95%CI -1.25, -0.70]. </P>
<P>Shiokawa grouped outcome measures on ESR, number of active joints, duration of morning stiffness and grip strength into a Rheumatoid Activity Index. The difference was statistically significant in favour of D-penicillamine [placebo: mean index score = 53 (SD 34.2), D-penicillamine = 36 (SD 23.2)].</P>
<P>As mentioned above, the efficacy data of the trial by Huskisson could not be pooled with the other studies. The results at six months showed a significant difference favouring d-penicillamine over placebo for pain, articular index and ESR. This study also included a third group treated with levamisole with results similar to those observed for d-penicillamine.</P>
<P>Three studies evaluated radiological changes (<LINK REF="STD-Andrews-1973" TYPE="STUDY">Andrews 1973</LINK>, <LINK REF="STD-Dixon-1975" TYPE="STUDY">Dixon 1975</LINK>, and <LINK REF="STD-Shiokawa-1977" TYPE="STUDY">Shiokawa 1977</LINK>). In Andrews all patients had advanced disease with severe erosive changes. Radiographs did not show any striking changes though most deteriorated. No significant differences in the number or severity of erosions were observed in Dixon's trial, and there was no evidence of a trend in either direction. In Shiokawa's study the radiographs were rated by two groups of assessors and the results were not pooled, only independently reported. The orthopedics group concluded there was no difference in response between treatment and placebo groups; however, the internist group concluded that erosive changes were less frequent in the D-penicillamine group. </P>
<P>Withdrawals and dropouts were available for all trials. No major differences were observed between placebo and low dose D-penicillamine (&lt; 500 mg/day). For higher dosages, patients on D-penicillamine were twice as likely to withdraw than those receiving placebo: 500 to &lt; 1000 mg/day OR = 1.63 [95%CI 1.05, 2.53], 1000 mg/day or more OR = 2.13 [95% CI 1.12, 4.06]. Though patients on d-penicillamine were less likely to withdraw because of lack of efficacy: 500mg &lt; 1000 mg/day OR = 0.41 [95% CI: 0.13, 1.29], 1000mg/day or more OR = 0.12 [95% CI 0.03, 0.56] they were three to five times more likely to dropout due to adverse reactions: 500mg &lt; 1000 mg/day OR = 2.60 [95% CI 1.51, 4.47], 1000mg/day or more OR = 4.95 [95% CI 2.38, 10.30].</P>
<P>Withdrawals due to adverse reactions did increase along with the dose of D-penicillamine (moderate dose 21%, high dose 25%) but this difference did not reach statistical significance.</P>
<P>Data from studies that reported specific reasons for withdrawal indicated no statistically significant differences between active treatment and placebo groups, mostly because of small numbers within each group of adverse events. The most frequent adverse effects responsible for D-penicillamine discontinuation were (all doses combined) hematological 6.6%, mucosal/cutaneous 4.9%, impaired/loss taste 4.7%, renal 4.1% or gastrointestinal 2.3%. </P>
<P>Adverse effects not requiring withdrawal occurred in both treatment and placebo groups. Statistically significant differences were only observed for impaired/loss of taste in the moderate dose group, OR = 3.74 [95% CI 1.61, 8.67] and the high dose group, OR = 3.07 [95% CI 1.57, 5.99].</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-07 23:56:51 -0500" MODIFIED_BY="[Empty name]">
<P>D-penicillamine has been used for the treatment of RA for several decades. Its use nevertheless has markedly declined in the past few years, mostly because of concerns over its safety. The purpose of this systematic review was to evaluate the effects of D-penicillamine for the treatment of patients with RA, when compared to placebo. </P>
<P>We only included in this review placebo-controlled trials, reporting results at approximately six months. Most of the trials included in this review are over 20 years old. The dosages evaluated ranged from 125 mg/day to 1,500 mg/day. Although some of the major outcome measures in the trials were sufficiently homogeneous to allow pooling, there was some lack of standardization of the outcome measurements (e.g. different joint count measures) and even complete omission of some outcomes. All these studies were published before the publication of OMERACT and the American College of Rheumatology (ACR) core set of measures for RA (<LINK REF="REF-OMERACT-1993" TYPE="REFERENCE">OMERACT 1993</LINK>, <LINK REF="REF-Felson-1993" TYPE="REFERENCE">Felson 1993</LINK>). We also encountered some difficulties in the data extraction given the lack of standardization in the data reported. Some trials reported results as changes from baseline, others as end-of-trial results. Standard deviations of the change or end-of-trial result were often not reported. We estimated missing data with approximate values derived from the trial per se (e.g. range as a measure of dispersion) or from results from the other trials (e.g. coefficient of variation to estimate standard deviations relative to the mean). Although these procedures may have created some bias, because they were similarly applied to both groups (treatment and control), their overall impact on the estimation of differences between groups is probably small. Our preference was to estimate some of these parameters as opposed to completely excluding some trials.</P>
<P>Statistically significant differences between placebo and D-penicillamine were observed for various measures of disease activity, including tender and swollen joint scores, pain global assessments and ESR. When using standardized mean differences, the effect sizes comparing D-penicillamine with placebo were generally about 0.5. This is considered to be a clinically relevant effect (<LINK REF="REF-Kazis-1989" TYPE="REFERENCE">Kazis 1989</LINK>) of moderate magnitude. None of the studies examined functional outcomes with comprehensive functional scales or health status measurements and therefore, these outcomes could not be adequately assessed. Three studies examined radiological progression; no clear trends favouring D-penicillamine were observed. </P>
<P>No significant differences in efficacy were observed between low, moderate and high dosages (only one trial evaluated a low dose). Nevertheless, withdrawals were significantly increased in the D-penicillamine group, mostly from toxicity, following a dose response pattern. The odds ratio for withdrawals due to adverse reactions was 2.6 in the moderate dose group and close to five in the higher dose group. These results suggest that on average, there is no advantage from using dosages higher than 500mg/d. </P>
<P>A few studies have compared the efficacy of D-penicillamine with that of other DMARDs, including gold, azathioprine and antimalarials (<LINK REF="REF-Huskisson-1974" TYPE="REFERENCE">Huskisson 1974</LINK>, <LINK REF="REF-Berry-1976" TYPE="REFERENCE">Berry 1976</LINK>, <LINK REF="REF-Bunch-1984" TYPE="REFERENCE">Bunch 1984</LINK>, <LINK REF="REF-Gibson-1987" TYPE="REFERENCE">Gibson 1987</LINK>, <LINK REF="REF-Scott-1990" TYPE="REFERENCE">Scott 1990</LINK>, <LINK REF="REF-Jessop-1998" TYPE="REFERENCE">Jessop 1998</LINK>). No consistent differences have been reported although some studies suggested better results with D-penicillamine when compared to antimalarials. Yet, treatment with penicillamine is associated with much higher adverse event rates. No major differences can be found when comparing the effect sizes in this meta-analysis with the results reported in the other Cochrane systematic reviews evaluating various DMARDs (<LINK REF="REF-Clark-1997" TYPE="REFERENCE">Clark 1997</LINK>, <LINK REF="REF-Suarez_x002d_Almazor-1998" TYPE="REFERENCE">Suarez-Almazor 1998</LINK>, <LINK REF="REF-Wells-1998" TYPE="REFERENCE">Wells 1998</LINK>). Given the high toxicity observed with D-penicillamine and the lack of evidence supporting a stronger beneficial effect, we would recommend the use of this drug only when treatment with some of the other less toxic DMARDs, such as methotrexate, sulphasalazine or antimalarials, has failed.</P>
<P>Most of the trials in this review included patients with long duration of disease, who had generally failed treatment with other DMARDs. Patients with early disease may respond better to treatment, and therefore it may be difficult to generalize the findings of this review to patients with early disease. Only one trial (<LINK REF="STD-Shiokawa-1977" TYPE="STUDY">Shiokawa 1977</LINK>) included patients with short disease duration, but the results did not appear to be substantially different from those reported in the other trials. This trial was not pooled with the others because of the way the outcomes were reported, as an aggregated index.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>D-penicillamine appears to be efficacious in the short-term treatment of patients with RA with a clinically and statistically significant benefit on disease activity. Its effects on long-term functional status and radiological progression are not clear at this time. There appears to be no clear advantage in using d-penicillamine in doses greater than 500mg/day. Higher dosages increase toxicity without a clear benefit on efficacy. There are no clear benefits of d-penicillamine when compared to other DMARDs, so we would recommend that other drugs with a lower risk-benefit ratio be used before D-penicillamine is prescribed.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Most trials included in this review were conducted over 20 years ago. Nevertheless, since the results across studies appear to be consistent and toxicity is high we would not recommend that any additional D-penicillamine, placebo-controlled trials be conducted in patients with RA. Although some direct drug-to-drug trials may be useful, more recently developed drugs increasingly being used in RA may be more promising, given their lower risk-benefit ratio. Because of the high costs involved in conducting clinical trials, research efforts may be better invested by evaluating other drugs.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The reviewers would like to acknowledge Dr. Ann Cranney and Dr. Dan Furst for their comments and suggestions, as well as the editors of the Cochrane Musculoskeletal Group for their editorial comments.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Maria Suarez-Almazor was the primary reviewer including protocol development then to ??? the review. C Spooner and E Belseck helped with data collection, quality assessment and data entry.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-08 00:12:59 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-08 00:12:59 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-08 00:12:59 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andrews-1973" MODIFIED="2008-11-08 00:12:59 -0500" MODIFIED_BY="[Empty name]" NAME="Andrews 1973" YEAR="1973.">
<REFERENCE MODIFIED="2008-11-08 00:12:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Multicentre Trial Group</AU>
<TI>Controlled trial of d-Penicillamine in severe rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>1</VL>
<NO>7798</NO>
<PG>275-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dixon-1975" NAME="Dixon 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Dixon ASt.J, Davies J, Dormandy TL, Hamilton EBD, Holt PJL, Mason RM, Thompson M, Weber JCP, Zutshi DW. Synthetic d-penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. Ann Rheum Dis 1975; 34:416-421.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dixon ASt</AU>
<TI>J, Davies J, Dormandy TL, Hamilton EBD, Holt PJL, Mason RM, Thompson M, Weber JCP, Zutshi DW. Synthetic d-penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen</TI>
<SO>Ann Rheum Dis</SO>
<YR>1975</YR>
<VL>34</VL>
<PG>416-421</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamilton-1977" MODIFIED="2008-11-07 23:46:46 -0500" MODIFIED_BY="[Empty name]" NAME="Hamilton 1977" YEAR="1977">
<REFERENCE MODIFIED="2008-11-07 23:46:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Hamilton ED, Dixon AS, David J, Dormandy TL, Holt PG, Mason RM, Thompson M, Weber JC, Zutshi DW</AU>
<TI>Multicenter trial with synthetic D-penicillamine in rheumatoid arthritis</TI>
<SO>Penicillamine research in rheumatoid arthritis</SO>
<YR>1977</YR>
<PG>215-8</PG>
<PB>Fabritius</PB>
<CY>Oslo</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huskisson-1976" MODIFIED="2008-11-07 23:37:01 -0500" MODIFIED_BY="[Empty name]" NAME="Huskisson 1976" YEAR="1976">
<REFERENCE MODIFIED="2008-11-07 23:37:01 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Huskisson EC, Scott J, Balme HW, Dieppe PA, Trapnell J, Willoughby DA. Immunostimulant therapy with levamisole for rheumatoid arthritis. Lancet 1976;: 393-95.&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 23:37:01 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huskisson EC, Scott J, Balme HW, Dieppe PA, Trapnell J, Willoughby DA</AU>
<TI>Immunostimulant therapy with levamisole for rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>1</VL>
<NO>7956</NO>
<PG>393-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mery-1976" NAME="Mery 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Mery C, Delrieu F, Ghozlan R, Saporta L, Simon F, Amor B, Menkes CJ, Delbarre F. Controlled trial of d-penicillamine in rheumatoid arthritis. Scand J Rheumatology 1976; 5:241-247.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mery C, Delrieu F, Ghozlan R, Saporta L, Simon F, Amor B, Menkes CJ, Delbarre F</AU>
<TI>Controlled trial of d-penicillamine in rheumatoid arthritis</TI>
<SO>Scand J Rheumatology</SO>
<YR>1976</YR>
<VL>5</VL>
<PG>241-247</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiokawa-1977" NAME="Shiokawa 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Shiokawa Y, Horiuchi Y, Honma M, Kageyama T, Okada T, Azuma T. Clinical evaluation of d-penicillamine by multicentric double-blind comparative study in chronic rheumatoid arthritis. Arthritis and Rheumatism 1977; 20: 1464-1472.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiokawa Y, Horiuchi Y, Honma M, Kageyama T, Okada T, Azuma T</AU>
<TI>Clinical evaluation of d-penicillamine by multicentric double-blind comparative study in chronic rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1977</YR>
<VL>20</VL>
<PG>1464-1472</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1983" NAME="Williams 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Williams HJ, Ward JR, Reading JC, Egger MJ, Grandone JT, Samuelson CO, Furst DE, Sullivan JM, Watson MA, Guttadauria M, Cathcart ES, Kaplan SB, Halla JT, Weinstein A, Plotz PH. Low-dose d-penicillamine therapy in rheumatoid arthritis. Arthritis and Rheumatism 1983; 26: 581-592&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams HJ, Ward JR, Reading JC, Egger MJ, Grandone JT, Samuelson CO, Furst DE, Sullivan JM, Watson MA, Guttadauria M, Cathcart ES, Kaplan SB, Halla JT, Weinstein A, Plotz PH</AU>
<TI>Low-dose d-penicillamine therapy in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1983</YR>
<VL>26</VL>
<PG>581-592</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-08 00:11:06 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahern_x002c_-1984" NAME="Ahern, 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Ahern MJ, Hall ND, Case K, Maddison PJ. D-penicillamine withdrawal in rheumatoid arthritis. Ann Rheumatic Dis 1984;43:213-217&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahern MJ, Hall ND, Case K, Maddison PJ</AU>
<TI>D-penicillamine withdrawal in rheumatoid arthritis</TI>
<SO>Ann Rheumatic Dis</SO>
<YR>1984</YR>
<VL>43</VL>
<PG>213-217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunch_x002c_-1984" NAME="Bunch, 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Bunch TW, O'Duffy JD, Tompkins RB, &amp;amp; O'Fallon WM. Controlled trial of hydroxychloroquine and d-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis &amp;amp; Rheumatism 1984;27(3):267-76&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunch TW, O'Duffy JD, Tompkins RB, &amp; O'Fallon WM</AU>
<TI>Controlled trial of hydroxychloroquine and d-penicillamine singly and in combination in the treatment of rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>3</NO>
<PG>267-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eberhardt_x002c_-1996" NAME="Eberhardt, 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eberhardt K, Rydgren L, Flex E, Svensson B, Wollheim FA</AU>
<TI>D-penicillamine in early rheumatoid arthritis: Experience from a 2-year double blind placebo controlled study</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>625-631</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Golding_x002c_-1973" MODIFIED="2008-11-08 00:11:06 -0500" MODIFIED_BY="[Empty name]" NAME="Golding, 1973" YEAR="1973">
<REFERENCE MODIFIED="2008-11-08 00:11:06 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Golding J R, Andrews FM, Camp V, Day AT, Freeman AM, Golding DN, Hill AGS, Lyle WH, Mowat AG. Controlled trial of penicillamine in severe rheumatoid arthritis. Ann Rheumatic Diseases 1973;&lt;br&gt;32(4):385-6&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 00:11:06 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Golding J R, Andrews FM, Camp V, Day AT, Freeman AM, Golding DN, Hill AGS, Lyle WH, Mowat AG</AU>
<TI>Controlled trial of penicillamine in severe rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1973</YR>
<VL>32</VL>
<NO>4</NO>
<PG>385-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Golding_x002c_-1977" MODIFIED="2008-11-07 23:45:35 -0500" MODIFIED_BY="[Empty name]" NAME="Golding, 1977" YEAR="1977">
<REFERENCE MODIFIED="2008-11-07 23:45:35 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Golding JR. Multicentre double blind controlled trial with semi-synthetic d-penicillamine in severe rheumatoid arthritis. In: Penicillamine research in rheumatoid disease. Oslo, Fabritius, 1977. pg 219-21&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 23:45:35 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Golding JR</AU>
<TI>Multicentre double blind controlled trial with semi-synthetic d-penicillamine in severe rheumatoid arthritis</TI>
<SO>Penicillamine research in rheumatoid disease</SO>
<YR>1977</YR>
<PG>219-21</PG>
<PB>Fabritius</PB>
<CY>Oslo</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Multicentre-Trial-Gr" MODIFIED="2008-11-07 23:48:20 -0500" MODIFIED_BY="[Empty name]" NAME="Multicentre Trial Gr" YEAR="1986">
<REFERENCE MODIFIED="2008-11-07 23:48:20 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The Multicentre Trial Group. A prospective five-year comparison of treatment which included penicillamine with that excluding penicillamine in early rheumatoid arthritis. Br J Rheum 1986;25:184-192&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 23:48:20 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Multicentre Trial Group</AU>
<TI>A prospective five-year comparison of treatment which included penicillamine with that excluding penicillamine in early rheumatoid arthritis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1986</YR>
<VL>25</VL>
<PG>184-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas_x002c_-1979" NAME="Thomas, 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Thomas MH. Rothermich NO. Philips VK. Bergen W. A controlled trial of penicillamine in rheumatoid arthritis. Ohio State Medical Journal 1979; 75(8):497-500&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas MH</AU>
<TI>Rothermich NO. Philips VK. Bergen W. A controlled trial of penicillamine in rheumatoid arthritis</TI>
<SO>Ohio State Medical Journal</SO>
<YR>1979</YR>
<VL>75</VL>
<NO>8</NO>
<PG>497-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Rijthoven_x002c_-1991" MODIFIED="2008-11-07 23:50:13 -0500" MODIFIED_BY="[Empty name]" NAME="van Rijthoven, 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-11-07 23:50:13 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;vanRijthoven AWAM, Dijkmans BAC, The HSG, Meijers KAE et al. Comparison of cyclosporine and d-penicillamine for rheumatoid arthritis: A randomized double blind multicentre study. J Rheumatol 1991;18(6)815-820.&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 23:50:13 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>vanRijthoven AWAM, Dijkmans BAC, The HSG, Meijers KAE et al</AU>
<TI>Comparison of cyclosporine and d-penicillamine for rheumatoid arthritis: A randomized double blind multicentre study</TI>
<SO>Journal of Rheumatology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>6</NO>
<PG>815-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verstraeten_x002c_-1990" NAME="Verstraeten, 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verstraeten A , Sileghem A, Dequeker J</AU>
<TI>OM-8980 and d-penicillamine in the treatment of rheumatoid arthritis</TI>
<SO>Scand J Rheumatol</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>422-431</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-08 00:09:32 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-08 00:09:32 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Berry-1976" MODIFIED="2008-11-08 00:09:32 -0500" MODIFIED_BY="[Empty name]" NAME="Berry 1976" TYPE="JOURNAL_ARTICLE">
<AU>Berry H, Liyange R, Durance CG, Berger L</AU>
<TI>Trial comparing azathioprine and and penicillamine in the treatment of rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1976</YR>
<VL>35</VL>
<PG>542</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunch-1984" MODIFIED="2008-11-08 00:08:40 -0500" MODIFIED_BY="[Empty name]" NAME="Bunch 1984" TYPE="JOURNAL_ARTICLE">
<AU>Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM</AU>
<TI>Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1984</YR>
<VL>27</VL>
<PG>267-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-1997" MODIFIED="2008-11-08 00:06:24 -0500" MODIFIED_BY="[Empty name]" NAME="Clark 1997" TYPE="COCHRANE_REVIEW">
<AU>Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, Suarez-Almazor ME</AU>
<TI>Injectable gold in rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-07 23:56:49 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 23:56:49 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000520  "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-11-08 00:06:32 -0500" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K</AU>
<TI>, Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1993" MODIFIED="2008-11-08 00:08:00 -0500" MODIFIED_BY="[Empty name]" NAME="Felson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M et al</AU>
<TI>The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>729-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibson-1987" MODIFIED="2008-11-08 00:07:18 -0500" MODIFIED_BY="[Empty name]" NAME="Gibson 1987" TYPE="JOURNAL_ARTICLE">
<AU>Gibson T, Emery P, Armstrong RD, Crisp AJ, Panayi GS</AU>
<TI>Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis - a comparative study</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1987</YR>
<VL>26</VL>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huskisson-1974" MODIFIED="2008-11-08 00:05:51 -0500" MODIFIED_BY="[Empty name]" NAME="Huskisson 1974" TYPE="JOURNAL_ARTICLE">
<AU>Huskisson EC, Gibson TJ, Balme HW et al</AU>
<TI>Trial comparing d-penicillamine and gold in rheumatoid arthritis. Preliminary report</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1974</YR>
<VL>33</VL>
<PG>532</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-11-08 00:05:32 -0500" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D, et al</AU>
<TI>Assessing the quality of reports of randomized trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jessop-1998" MODIFIED="2008-11-08 00:04:45 -0500" MODIFIED_BY="[Empty name]" NAME="Jessop 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jessop JD, O'Sullivan MM, Lewis PA et al</AU>
<TI>A long-term 5-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1998</YR>
<VL>37</VL>
<PG>992-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kazis-1989" NAME="Kazis 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kazis LEE, Anderson JJ, Meenan RF</AU>
<TI>Effect sizes for interpreting changes in health status</TI>
<SO>Medical Care</SO>
<YR>1989</YR>
<VL>27</VL>
<NO>S3</NO>
<PG>S178-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OMERACT-1993" MODIFIED="2008-11-08 00:03:36 -0500" MODIFIED_BY="[Empty name]" NAME="OMERACT 1993" TYPE="JOURNAL_ARTICLE">
<AU>OMERACT</AU>
<TI>Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials</TI>
<SO>Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>526-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-1990" MODIFIED="2008-11-08 00:02:50 -0500" MODIFIED_BY="[Empty name]" NAME="Scott 1990" TYPE="JOURNAL_ARTICLE">
<AU>Scott DL, Greenwood A, Davies J, Maddison PJ, Maddison MC, Hall ND</AU>
<TI>Radiologic progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1990</YR>
<VL>29</VL>
<PG>126-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-1998" MODIFIED="2008-11-08 00:01:39 -0500" MODIFIED_BY="[Empty name]" NAME="Suarez-Almazor 1998" TYPE="COCHRANE_PROTOCOL">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P</AU>
<TI>Rheumatoid arthritis: Antimalarials vs. placebo</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<PG>Antimalarials vs. placebo. 1998 Oxford, UK</PG>
<IDENTIFIERS MODIFIED="2008-11-07 23:21:47 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 23:21:47 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000959 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-1998a" MODIFIED="2008-11-08 00:01:31 -0500" MODIFIED_BY="[Empty name]" NAME="Suarez-Almazor 1998a" TYPE="COCHRANE_REVIEW">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P</AU>
<TI>Methotrexate for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>2</NO>
<PG>Methotrexate vs. placebo. 1998 Oxford, UK</PG>
<IDENTIFIERS MODIFIED="2008-11-07 23:23:04 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 23:23:04 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000957"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-1998b" MODIFIED="2008-11-08 00:01:25 -0500" MODIFIED_BY="[Empty name]" NAME="Suarez-Almazor 1998b" TYPE="COCHRANE_REVIEW">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P</AU>
<TI>Sulfasalazine for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>2</NO>
<PG>Sulfasalazine vs. placebo. 1998 Oxford, UK</PG>
<IDENTIFIERS MODIFIED="2008-11-07 23:26:54 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 23:26:54 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000958"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-1998c" MODIFIED="2008-11-08 00:01:19 -0500" MODIFIED_BY="[Empty name]" NAME="Suarez-Almazor 1998c" TYPE="COCHRANE_PROTOCOL">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P</AU>
<TI>Cyclophosphamide for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<IDENTIFIERS MODIFIED="2008-11-07 23:29:15 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 23:29:15 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001157"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wells-1998" MODIFIED="2008-11-08 00:01:04 -0500" MODIFIED_BY="[Empty name]" NAME="Wells 1998" TYPE="COCHRANE_REVIEW">
<AU>Wells G, Haguenauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell</AU>
<TI>Cyclosporine for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-07 23:32:15 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 23:32:15 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001083 "/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Andrews-1973">
<CHAR_METHODS>
<P>Allocation: Randomized [stratified by age (at 45y) sex and steroid use]<BR/>Blinding: double blind<BR/>Design: parallel study<BR/>Sample size entry: Penicillamine n= 52; placebo n = 53<BR/>Analysis: completers.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK, 5 centres<BR/>Patients with active RA (severe disease)<BR/>Age: mean 56.5 yrs (sd 22)<BR/>Duration of disease: mean 11.2 yrs (sd 8.7)<BR/>Females: 79%<BR/>RF: 65%<BR/>Concomitant use of steroids: 64.7%<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: none in past 2 mo. No gold past 6 mo.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Penicillamine: 1500 gm/day or matching placebo<BR/>Treatment duration: 12 months<BR/>1/2 the patients in each group received 5 ml of 0.1% copper supplement daily, other 1/2 received 5 ml of 0.1% sodium bicarbonate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Articular index: Ritchie (extended to include joint swelling (scale 0- 182, 182 = worst)<BR/>Patient assessment: Well being (scale 0-3, 3 = very ill)<BR/>Physician assessment: Observer assessment scale 1-3. (3 = no value, 1 = successful)<BR/>Pain: (scale 0-3, 3 = severe)<BR/>Functional assessment: (scale 0-192, 192 = worst possible)<BR/>ESR<BR/>Xray: joints scored by CIOMS method</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 5<BR/>Allocation concealment: A<BR/>Reported: end of trial data, mean score only<BR/>Calculated:end of trial sd for articular index, function &amp; ESR from baseline range / 3 (using baseline scores for completers only)<BR/>sd pain calculated using coefficient of variation from studies. <BR/>Observer assessment converted to 3 point scale, (3=worse). mean and sd calculated</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dixon-1975">
<CHAR_METHODS>
<P>Allocation: Randomized (subgrouped by 'general' or 'nodule' groups)<BR/>Blinding: double blind<BR/>Design: parallel study, two doses vs placebo<BR/>Sample size at entry: penicillamine 600 mg/day n=34; 1200 mg/day n= 44; control 12mg/day n= 43<BR/>Analysis: completers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK, 5 centres<BR/>Patients with active RA<BR/>Age: mean 53.4 y (sd 9.6)<BR/>Duration of disease: mean 8.7y (sd 7.6)<BR/>Females: 68%<BR/>RF: 100%<BR/>Concomitant use of steroids: 62%<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: excluded from study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Synthetic d-penicillamine: 600 mg/day, or 1200 mg/day or control with 12 mg/day<BR/>Treatment duration: 24 wks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (scale 0 to 4, 4 = very severe)<BR/>ESR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Allocation concealment: B<BR/>Reported: baseline &amp; mean differences using combined results for all subgroups<BR/>Baseline pain score: mean &amp; sd calculated from table 1. Baseline sd imputed to end of trial result<BR/>Reported: change in ESR, calculated end of trial score, imputed sd from CV = 0.7</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hamilton-1977">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Huskisson-1976">
<CHAR_METHODS>
<P>Allocation: not reported<BR/>Blinding: Single blind (observer)<BR/>Design: not reported<BR/>Sample size at entry: penicillamine n= 12; levamisole n = 12; placebo n = 10.<BR/>Analysis: intention to treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK, single centre<BR/>Patients with active RA<BR/>Age: not reported<BR/>Duration of disease: not reported<BR/>Females: not reported<BR/>RF: not reported<BR/>Concomitant use of steroids: not reported <BR/>Concomitant use of other DMARDS: not reported <BR/>Previous use of DMARDS: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Penicillamine 1000 mg/day or Levamisole 150 mg/day or placebo<BR/>Treatment duration: 6 mos</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Articular index: Ritchie<BR/>Pain: VAS<BR/>ESR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 2<BR/>Allocation concealment: C<BR/>Reported: Change scores, no baseline data<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mery-1976">
<CHAR_METHODS>
<P>Allocation: Randomized<BR/>Blinding: double blind (4 months then became open study)<BR/>Design: parallel study<BR/>Sample size at entry: 66, each treatment group subgrouped to receive zinc supplement or not. n = 31 when zinc groups not included. Penicillamine 500 mg/day n =10; penicillamine 1000 mg/day n = 10; placebo n = 11<BR/>Analysis: intention to treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: France<BR/>Patients with active RA<BR/>Age: mean 52.3 yrs<BR/>Duration of disease: 9.5 yrs<BR/>Females: 71%<BR/>RF: 80.6%<BR/>Concomitant use of steroids: 76.7%<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: none in past 3 mo.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>D-penicillamine 500 mg/day or d-penicillamine 1000 mg/day or placebo<BR/>Treatment duration: 4 mo.<BR/>Half of each group received 5 mg/day zinc supplement therefore six groups studied.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Articular index: Ritchie<BR/>Patient assessment: 7 grade scale, low score = worse<BR/>Physician assessment: 7 grade scale, low score = worse<BR/>ESR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 3<BR/>Allocation concealment: B<BR/>Only groups without zinc included. Zn supplement found to inhibit effect of d-penicillamine<BR/>Reported: Baseline &amp; change scores, sd imputed from SE's at baseline and applied to end of trial results.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shiokawa-1977">
<CHAR_METHODS>
<P>Allocation: Randomized<BR/>Blinding: double blind<BR/>Sample size at entry: penicillamine n = 90; control n = 89<BR/>Analysis: completers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan, multicentre<BR/>Patients with active RA<BR/>Age: mean 48.6 y<BR/>Duration of disease: mean 13 mo.<BR/>Females: 84%<BR/>RF: 79% Concomitant use of steroids: none<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: none in previous two months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Penicillamine: Tx group 600 mg/day, control group 30 mg/day<BR/>Treatment duration: 24 wks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physician global assessment: 4 category scale<BR/>Xray</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Allocation concealment: A<BR/> MD assessment converted to 4 point scale: Excellent = 1, Good = 2, Moderate = 3, Poor = 4. Mean &amp; sd calculated<BR/>X-ray results not pooled with other studies.<BR/>Four outcomes were grouped into a 'rheumatoid activity index' and not reported separately.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Williams-1983">
<CHAR_METHODS>
<P>Allocation: randomized<BR/>Blinding: double blind<BR/>Design: parallel study<BR/>Sample size at entry: 225. d-penicillamine 125 mg/day, n = 87; d-penicillamine 500 mg/day, n = 86; placebo n = 52<BR/>Analysis: completers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA, 10 centres<BR/>Patients with active RA<BR/>Age: mean 51 yrs sd 11.4 <BR/>Females: 68%<BR/>Duration of disease: mean 9.7 yrs (sd 8.2)<BR/>RF: not reported<BR/>Concomitant use of steroids: 33%<BR/>Concomitant use of other DMARDS: none<BR/>Previous use of DMARDS: not in past 2 to 3 mo.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Penicillamine 125 mg/day or Penicillamine 500 mg/day or placebo<BR/>Treatment duration: 36 wks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints: count (max 60 joints)<BR/>Pain: Joint tenderness (scale 0-3, 3 = severe)<BR/>Swollen joints: count and score (scale 0-3, 3 = severe)<BR/>Patient's assessment: (scale 1-5, 5 = very severe)<BR/>Physician's assessment: (scale 1-5, 5 = very severe)<BR/>ESR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score : 4<BR/>Allocation concealment: B<BR/>Reported: change scores with sd <BR/>Calculated end of trial scores. Used baseline sd values</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ahern_x002c_-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studied effects of withdrawal of d-penicillamine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bunch_x002c_-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination therapy. No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eberhardt_x002c_-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long term study and data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Golding_x002c_-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report on MCTG study (Andrews 1973)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Golding_x002c_-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report on the MCTG (Andrews 1973)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Multicentre-Trial-Gr">
<CHAR_REASON_FOR_EXCLUSION>
<P>Results at 5 yr only. No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thomas_x002c_-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Placebo group data not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Rijthoven_x002c_-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group. Drug/drug comparison</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Verstraeten_x002c_-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Andrews-1973">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dixon-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hamilton-1977">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Huskisson-1976">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mery-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Shiokawa-1977">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Williams-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>D-Penicillamine vs. placebo - Efficacy</NAME>
<CONT_OUTCOME CHI2="2.1691686605449796" CI_END="-3.5517100640252264" CI_START="-10.021445485909236" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.786577774967231" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.7046776430590005" P_Q="0.8295172486926508" P_Z="3.924186518952184E-5" Q="0.3738228726497406" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="178" TOTAL_2="138" UNITS="" WEIGHT="99.99999999999999" Z="4.11189860167182">
<NAME>Tender joints</NAME>
<GROUP_LABEL_1>D-Penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6367728361162" CI_START="-11.3632271638838" DF="0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.028331209383414043" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="39" WEIGHT="36.379830017416495" Z="2.1926693663902976">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<CONT_DATA CI_END="-0.6367728361162" CI_START="-11.3632271638838" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="29.0" ORDER="137491" SD_1="13.9" SD_2="13.4" SE="2.736390671557361" STUDY_ID="STD-Williams-1983" TOTAL_1="67" TOTAL_2="39" WEIGHT="36.379830017416495"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8650710344658568" CI_END="-1.8447990811131012" CI_START="-11.369685324507657" DF="1" EFFECT_SIZE="-6.6072422028103786" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.35232356938284437" P_Z="0.006544329143511011" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="50" WEIGHT="46.13743498669415" Z="2.7191834996711157">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<CONT_DATA CI_END="6.137520974641916" CI_START="-12.017520974641915" EFFECT_SIZE="-2.9399999999999995" ESTIMABLE="YES" MEAN_1="12.48" MEAN_2="15.42" ORDER="137492" SD_1="10.6" SD_2="10.6" SE="4.6314733567781055" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" WEIGHT="12.699263304357215"/>
<CONT_DATA CI_END="-2.405835107746264" CI_START="-13.594164892253737" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="29.0" ORDER="137493" SD_1="14.7" SD_2="13.4" SE="2.8542182082833127" STUDY_ID="STD-Williams-1983" TOTAL_1="61" TOTAL_2="39" WEIGHT="33.438171682336936"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9302747534293823" CI_END="-1.160009264874848" CI_START="-16.63326963059425" DF="1" EFFECT_SIZE="-8.896639447734549" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="0.3347916927878556" P_Z="0.02420650928723492" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="49" WEIGHT="17.482734995889338" Z="2.2538356479322808">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<CONT_DATA CI_END="-0.30942966832006213" CI_START="-29.890570331679932" EFFECT_SIZE="-15.099999999999998" ESTIMABLE="YES" MEAN_1="31.3" MEAN_2="46.4" ORDER="137494" SD_1="30.0" SD_2="32.0" SE="7.546348018813645" STUDY_ID="STD-Andrews-1973" TOTAL_1="30" TOTAL_2="38" WEIGHT="4.783471691532122"/>
<CONT_DATA CI_END="2.517520974641915" CI_START="-15.637520974641916" EFFECT_SIZE="-6.5600000000000005" ESTIMABLE="YES" MEAN_1="8.86" MEAN_2="15.42" ORDER="137495" SD_1="10.6" SD_2="10.6" SE="4.6314733567781055" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" WEIGHT="12.699263304357215"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0629210743626856" CI_END="-0.5953467070365726" CI_START="-6.294719287286071" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.445032997161322" ESTIMABLE="YES" I2="5.91963748582295" I2_Q="5.91963748582295" ID="CMP-001.02" NO="2" P_CHI2="0.302550289766379" P_Q="0.302550289766379" P_Z="0.017815384907184085" Q="1.0629210743626856" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="78" UNITS="" WEIGHT="200.0" Z="2.3694329524576143">
<NAME>Number of swollen joints</NAME>
<GROUP_LABEL_1>D-Penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9581941409087786" CI_START="-5.958194140908779" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.3220116799687339" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="39" WEIGHT="100.0" Z="0.990332416635864">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<CONT_DATA CI_END="1.9581941409087786" CI_START="-5.958194140908779" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="20.0" ORDER="137496" SD_1="9.9" SD_2="10.1" SE="2.0195239158119787" STUDY_ID="STD-Williams-1983" TOTAL_1="67" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8940013879748827" CI_START="-9.105998612025118" DF="0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.016999985613137116" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="39" WEIGHT="100.0" Z="2.3867080456383563">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<CONT_DATA CI_END="-0.8940013879748827" CI_START="-9.105998612025118" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="20.0" ORDER="137497" SD_1="10.4" SD_2="10.1" SE="2.094935745969166" STUDY_ID="STD-Williams-1983" TOTAL_1="61" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.111912593659589" CI_END="-0.38878713049801294" CI_START="-0.8532878006839762" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6210374655909946" ESTIMABLE="YES" I2="43.75633913771551" I2_Q="28.403253928730102" ID="CMP-001.03" NO="3" P_CHI2="0.1300910751101907" P_Q="0.2474095045124428" P_Z="1.5975695289540017E-7" Q="2.793423039098914" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="232" TOTAL_2="202" UNITS="" WEIGHT="300.0" Z="5.240944281613505">
<NAME>Pain</NAME>
<GROUP_LABEL_1>D-Penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.193141671028263" CI_START="-23.193141671028265" DF="0" EFFECT_SIZE="-11.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="0.07703171316064528" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="39" WEIGHT="100.0" Z="1.76817463551397">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<CONT_DATA CI_END="1.193141671028263" CI_START="-23.193141671028265" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="43.0" ORDER="137498" SD_1="28.1" SD_2="32.4" SE="6.221104962747381" STUDY_ID="STD-Williams-1983" TOTAL_1="67" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.211993947238213" CI_END="-0.26409326892460827" CI_START="-0.9979938199946707" DF="1" EFFECT_SIZE="-0.6310435444596395" ESTIMABLE="YES" I2="76.25827547412085" ID="CMP-001.03.02" NO="2" P_CHI2="0.040139271279928446" P_Z="7.501950138080048E-4" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="82" WEIGHT="100.00000000000001" Z="3.3705455542008975">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<CONT_DATA CI_END="-0.25289819449497597" CI_START="-0.9871018055050242" EFFECT_SIZE="-0.6200000000000001" ESTIMABLE="YES" MEAN_1="1.62" MEAN_2="2.24" ORDER="137499" SD_1="0.66" SD_2="0.97" SE="0.1873002812300003" STUDY_ID="STD-Dixon-1975" TOTAL_1="33" TOTAL_2="43" WEIGHT="99.91746229850794"/>
<CONT_DATA CI_END="-1.2273493758063676" CI_START="-26.77265062419363" EFFECT_SIZE="-14.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="43.0" ORDER="137500" SD_1="30.8" SD_2="32.4" SE="6.516778229060671" STUDY_ID="STD-Williams-1983" TOTAL_1="61" TOTAL_2="39" WEIGHT="0.08253770149207212"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1064956073224615" CI_END="-0.3079885236757112" CI_START="-0.908132169480756" DF="1" EFFECT_SIZE="-0.6080603465782336" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" NO="3" P_CHI2="0.7441696979873801" P_Z="7.138040600758665E-5" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="81" WEIGHT="100.0" Z="3.9716370840571287">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<CONT_DATA CI_END="-0.14363358332225912" CI_START="-0.9763664166777406" EFFECT_SIZE="-0.5599999999999998" ESTIMABLE="YES" MEAN_1="1.36" MEAN_2="1.92" ORDER="137501" SD_1="0.9" SD_2="0.83" SE="0.21243574880048097" STUDY_ID="STD-Andrews-1973" TOTAL_1="30" TOTAL_2="38" WEIGHT="51.939653421766295"/>
<CONT_DATA CI_END="-0.22715563558996543" CI_START="-1.092844364410035" EFFECT_SIZE="-0.6600000000000001" ESTIMABLE="YES" MEAN_1="1.58" MEAN_2="2.24" ORDER="137502" SD_1="1.05" SD_2="0.97" SE="0.22084301947599844" STUDY_ID="STD-Dixon-1975" TOTAL_1="41" TOTAL_2="43" WEIGHT="48.0603465782337"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.555918137085683" CI_END="-0.6129231410967948" CI_START="-0.910653824926015" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7617884830114049" ESTIMABLE="YES" I2="74.03927611452795" I2_Q="78.31465981233775" ID="CMP-001.04" NO="4" P_CHI2="0.009070091521901968" P_Q="0.009937815051714205" P_Z="1.1283387291608258E-23" Q="9.222820498513041" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="196" UNITS="" WEIGHT="300.0" Z="10.029721971123363">
<NAME>Physician global assessment</NAME>
<GROUP_LABEL_1>D-Penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="1.3176038655700188E-31" CI_END="-0.12026607898381014" CI_START="-0.7197339210161896" DF="0" EFFECT_SIZE="-0.4199999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.0" P_Z="0.0060255927735917885" STUDIES="1" TAU2="0.0" TOTAL_1="68" TOTAL_2="40" WEIGHT="100.0" Z="2.74638542983715">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<CONT_DATA CI_END="-0.1202660789838102" CI_START="-0.7197339210161897" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="3.0" ORDER="137503" SD_1="0.78" SD_2="0.76" SE="0.15292827999925132" STUDY_ID="STD-Williams-1983" TOTAL_1="68" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.333097638572643" CI_END="-0.5614565094270579" CI_START="-0.9836982899095116" DF="1" EFFECT_SIZE="-0.7725773996682848" ESTIMABLE="YES" I2="57.13852761808177" ID="CMP-001.04.02" NO="2" P_CHI2="0.12664977502577057" P_Z="7.374423684318669E-13" STUDIES="2" TAU2="0.0" TOTAL_1="121" TOTAL_2="113" WEIGHT="100.0" Z="7.172307188025271">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<CONT_DATA CI_END="-0.6395132482100179" CI_START="-1.2604867517899825" EFFECT_SIZE="-0.9500000000000002" ESTIMABLE="YES" MEAN_1="2.15" MEAN_2="3.1" ORDER="137504" SD_1="0.94" SD_2="0.87" SE="0.15841451896007383" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="60" TOTAL_2="73" WEIGHT="46.23557565705595"/>
<CONT_DATA CI_END="-0.33207212737446706" CI_START="-0.9079278726255331" EFFECT_SIZE="-0.6200000000000001" ESTIMABLE="YES" MEAN_1="2.38" MEAN_2="3.0" ORDER="137505" SD_1="0.66" SD_2="0.76" SE="0.14690467523723463" STUDY_ID="STD-Williams-1983" TOTAL_1="61" TOTAL_2="40" WEIGHT="53.764424342944054"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7758581789178576" CI_START="-1.364141821082142" DF="0" EFFECT_SIZE="-1.0699999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="1.00541917145542E-12" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="43" WEIGHT="100.0" Z="7.129762968565436">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<CONT_DATA CI_END="-0.7758581789178576" CI_START="-1.364141821082142" EFFECT_SIZE="-1.0699999999999998" ESTIMABLE="YES" MEAN_1="1.46" MEAN_2="2.53" ORDER="137506" SD_1="0.72" SD_2="0.63" SE="0.15007511536043283" STUDY_ID="STD-Andrews-1973" TOTAL_1="39" TOTAL_2="43" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8921953280933377" CI_END="-0.2510711726519226" CI_START="-0.6660275209714408" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4585493468116817" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.3448832004404393" P_Q="0.3448832004404393" P_Z="1.4793978897308831E-5" Q="0.8921953280933377" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="161" TOTAL_2="118" UNITS="" WEIGHT="200.0" Z="4.331733728258225">
<NAME>Patient global assessment</NAME>
<GROUP_LABEL_1>D-Penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06868691559174978" CI_START="-0.6513130844082509" DF="0" EFFECT_SIZE="-0.3600000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.015431451534699893" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="40" WEIGHT="100.0" Z="2.4220918049997366">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<CONT_DATA CI_END="-0.06868691559174978" CI_START="-0.6513130844082509" EFFECT_SIZE="-0.3600000000000003" ESTIMABLE="YES" MEAN_1="2.61" MEAN_2="2.97" ORDER="137507" SD_1="0.83" SD_2="0.7" SE="0.148631855843317" STUDY_ID="STD-Williams-1983" TOTAL_1="70" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2644298715982811" CI_START="-0.855570128401719" DF="0" EFFECT_SIZE="-0.56" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="1.0" P_Z="2.0446671588640887E-4" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="40" WEIGHT="100.0" Z="3.71343287387511">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<CONT_DATA CI_END="-0.2644298715982811" CI_START="-0.855570128401719" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="2.97" ORDER="137508" SD_1="0.8" SD_2="0.7" SE="0.15080385697550486" STUDY_ID="STD-Williams-1983" TOTAL_1="61" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.75" MEAN_2="1.0" ORDER="137509" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Andrews-1973" TOTAL_1="30" TOTAL_2="38" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.225146571629622" CI_START="-37.025146571629634" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.900000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2387608273096259" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.1780898037000818">
<NAME>Functional status</NAME>
<GROUP_LABEL_1>D-Penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.225146571629622" CI_START="-37.025146571629634" DF="0" EFFECT_SIZE="-13.900000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.2387608273096259" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="38" WEIGHT="100.0" Z="1.1780898037000818">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<CONT_DATA CI_END="9.225146571629622" CI_START="-37.025146571629634" EFFECT_SIZE="-13.900000000000006" ESTIMABLE="YES" MEAN_1="56.5" MEAN_2="70.4" ORDER="137510" SD_1="51.0" SD_2="44.67" SE="11.79876097420046" STUDY_ID="STD-Andrews-1973" TOTAL_1="30" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.231702905900324" CI_END="-5.882378056453519" CI_START="-17.941154186248664" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.911766121351091" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.5165615285053846" P_Q="0.7178532649205909" P_Z="1.0788410675211997E-4" Q="0.6629803764983131" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="170" TOTAL_2="170" UNITS="" WEIGHT="300.0" Z="3.872139649798628">
<NAME>ESR</NAME>
<GROUP_LABEL_1>D-Penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.0078095632311825" CI_START="-22.007809563231184" DF="0" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.26298873255831645" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="24" WEIGHT="100.0" Z="1.119355014468343">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day (change scores)</NAME>
<CONT_DATA CI_END="6.0078095632311825" CI_START="-22.007809563231184" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-3.0" ORDER="137511" SD_1="23.3" SD_2="30.6" SE="7.146972941198408" STUDY_ID="STD-Williams-1983" TOTAL_1="45" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7819203593795803" CI_END="-0.4054336397904983" CI_START="-20.891372552240426" DF="1" EFFECT_SIZE="-10.648403096015462" ESTIMABLE="YES" I2="43.88076915243424" ID="CMP-001.07.02" NO="2" P_CHI2="0.18191382607652617" P_Z="0.04159569803247649" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="54" WEIGHT="100.0" Z="2.037542594483818">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<CONT_DATA CI_END="-2.4209454588847805" CI_START="-24.519054541115217" EFFECT_SIZE="-13.469999999999999" ESTIMABLE="YES" MEAN_1="28.5" MEAN_2="41.97" ORDER="137512" SD_1="19.95" SD_2="29.38" SE="5.637376313171441" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" WEIGHT="85.94122120585682"/>
<CONT_DATA CI_END="33.918199914252554" CI_START="-20.718199914252555" EFFECT_SIZE="6.600000000000001" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="34.4" ORDER="137513" SD_1="31.9" SD_2="31.9" SE="13.938113215209581" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" WEIGHT="14.058778794143173"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7868021700224308" CI_END="-5.583132682768003" CI_START="-23.20575943495981" DF="2" EFFECT_SIZE="-14.394446058863906" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" NO="3" P_CHI2="0.40926148978078924" P_Z="0.0013654312589693135" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="92" WEIGHT="99.99999999999999" Z="3.2018604546871936">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<CONT_DATA CI_END="-5.42683802685627" CI_START="-42.573161973143726" EFFECT_SIZE="-24.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="56.0" ORDER="137514" SD_1="39.67" SD_2="37.67" SE="9.476277176339188" STUDY_ID="STD-Andrews-1973" TOTAL_1="30" TOTAL_2="38" WEIGHT="22.506584960332265"/>
<CONT_DATA CI_END="-2.212487848656785" CI_START="-23.727512151343213" EFFECT_SIZE="-12.969999999999999" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="41.97" ORDER="137515" SD_1="20.3" SD_2="29.38" SE="5.488627462645792" STUDY_ID="STD-Dixon-1975" TOTAL_1="41" TOTAL_2="43" WEIGHT="67.08997096630745"/>
<CONT_DATA CI_END="24.51819991425256" CI_START="-30.118199914252553" EFFECT_SIZE="-2.799999999999997" ESTIMABLE="YES" MEAN_1="31.6" MEAN_2="34.4" ORDER="137516" SD_1="31.9" SD_2="31.9" SE="13.938113215209581" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" WEIGHT="10.403444073360284"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>D-Penicillaminevs. placebo - Withdrawals and dropouts</NAME>
<DICH_OUTCOME CHI2="9.816473957390865" CI_END="2.137926546760776" CI_START="1.103333591204768" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.535853565470867" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="73" I2="18.50434244796457" I2_Q="50.3454154258057" ID="CMP-002.01" LOG_CI_END="0.3299927799726328" LOG_CI_START="0.04270684055949557" LOG_EFFECT_SIZE="0.18634981026606412" METHOD="PETO" NO="1" P_CHI2="0.27814417920087164" P_Q="0.13346566142928284" P_Z="0.011000414811426825" Q="4.027825460933185" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="425" TOTAL_2="364" WEIGHT="300.0" Z="2.542685642001568">
<NAME>Withdrawals and dropouts - Total</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6916734372861146" CI_START="0.33847637831104277" DF="0" EFFECT_SIZE="0.7566977589087978" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.22831653005481825" LOG_CI_START="-0.4704716345922195" LOG_EFFECT_SIZE="-0.12107755226870065" NO="1" P_CHI2="1.0" P_Z="0.4970126367430321" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="99.99999999999999" Z="0.6791976561388522">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="1.6916734372861146" CI_START="0.33847637831104277" EFFECT_SIZE="0.7566977589087978" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.22831653005481825" LOG_CI_START="-0.4704716345922195" LOG_EFFECT_SIZE="-0.12107755226870065" ORDER="137517" O_E="-1.6546762589928043" SE="0.410471626970872" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="5.935177538294669" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6594623538551547" CI_END="2.5281963828772698" CI_START="1.051212257025624" DF="3" EFFECT_SIZE="1.6302364938402136" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="42" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.4028108056417525" LOG_CI_START="0.02169041607373368" LOG_EFFECT_SIZE="0.21225061085774305" NO="2" P_CHI2="0.645983592798443" P_Z="0.02903169542000938" STUDIES="4" TAU2="0.0" TOTAL_1="220" TOTAL_2="195" WEIGHT="100.0" Z="2.183055876119995">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="6.239146879516481" CI_START="0.7233000856018352" EFFECT_SIZE="2.1243294170247453" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.7951252097388196" LOG_CI_START="-0.1406814835045672" LOG_EFFECT_SIZE="0.32722186311712625" ORDER="137518" O_E="2.4935064935064934" SE="0.5496974839290061" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="3.309424683313952" WEIGHT="16.586397653332657"/>
<DICH_DATA CI_END="5.765765430770378" CI_START="0.04857408165219591" EFFECT_SIZE="0.5292133415000503" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7608569699643885" LOG_CI_START="-1.3135954014776179" LOG_EFFECT_SIZE="-0.2763692157566148" ORDER="137519" O_E="-0.4285714285714286" SE="1.2185435916898848" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.673469387755102" WEIGHT="3.375339263338936"/>
<DICH_DATA CI_END="3.6624394194191874" CI_START="0.9957367001522311" EFFECT_SIZE="1.909666290742944" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="19" LOG_CI_END="0.5637704497363496" LOG_CI_START="-0.001855485660859591" LOG_EFFECT_SIZE="0.28095748203774495" ORDER="137520" O_E="5.860335195530727" SE="0.332251474345857" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="9.058706032895355" WEIGHT="45.401033371090065"/>
<DICH_DATA CI_END="2.744987725982539" CI_START="0.6179660406190318" EFFECT_SIZE="1.3024243534936182" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="14" LOG_CI_END="0.4385404068735527" LOG_CI_START="-0.20903539024612436" LOG_EFFECT_SIZE="0.11475250831371417" ORDER="137521" O_E="1.8260869565217384" SE="0.38038922877999254" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="6.911042733155795" WEIGHT="34.637229712238344"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.129186142602525" CI_END="4.057879729861865" CI_START="1.116526513171977" DF="3" EFFECT_SIZE="2.1285512222293153" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="17" I2="27.346457718441016" ID="CMP-002.01.03" LOG_CI_END="0.6082991709793935" LOG_CI_START="0.047869040338557226" LOG_EFFECT_SIZE="0.3280841056589753" NO="3" P_CHI2="0.24784813102625758" P_Z="0.021745509605173817" STUDIES="4" TAU2="0.0" TOTAL_1="118" TOTAL_2="117" WEIGHT="100.00000000000003" Z="2.2947839376742114">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="2.949567845515971" CI_START="0.35446741881935195" EFFECT_SIZE="1.0225095113653484" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.46975839019641297" LOG_CI_START="-0.45042367720093224" LOG_EFFECT_SIZE="0.009667356497740403" ORDER="137522" O_E="0.07619047619047592" SE="0.5405195013638958" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="3.422766439909297" WEIGHT="37.0932957237347"/>
<DICH_DATA CI_END="9.49442745656676" CI_START="1.5593116158318805" EFFECT_SIZE="3.847696845997315" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.9774687805579428" LOG_CI_START="0.1929329141065783" LOG_EFFECT_SIZE="0.5852008473322605" ORDER="137523" O_E="6.344827586206897" SE="0.46084025146870294" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="4.708680142687277" WEIGHT="51.02903398977026"/>
<DICH_DATA CI_END="320.39687109040506" CI_START="0.12210257817129111" EFFECT_SIZE="6.254700951936332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.505688266229907" LOG_CI_START="-0.9132751659179834" LOG_EFFECT_SIZE="0.7962065501559619" ORDER="137524" O_E="0.4545454545454546" SE="2.008316044185609" STUDY_ID="STD-Huskisson-1976" TOTAL_1="12" TOTAL_2="10" VAR="0.2479338842975206" WEIGHT="2.6869157015650376"/>
<DICH_DATA CI_END="9.39890589772916" CI_START="0.13318790102304082" EFFECT_SIZE="1.1188478665268242" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9730773014471441" LOG_CI_START="-0.8755352252977506" LOG_EFFECT_SIZE="0.04877103807469681" ORDER="137525" O_E="0.09523809523809534" SE="1.0858841489895403" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.8480725623582765" WEIGHT="9.190754584930025"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.659204571977666" CI_END="0.6127028908931982" CI_START="0.13011462862572895" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2823501533671958" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.2127500705477558" LOG_CI_START="-0.8856738735054299" LOG_EFFECT_SIZE="-0.5492119720265929" METHOD="PETO" NO="2" P_CHI2="0.6460413769679965" P_Q="0.4432350073675868" P_Z="0.0013777150101505896" Q="1.6273112549586102" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="315" TOTAL_2="246" WEIGHT="300.0" Z="3.1992795627651405">
<NAME>Withdrawals: lack of effect</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.406374156841732" CI_START="0.0743776064822415" DF="0" EFFECT_SIZE="0.3234234741084335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.1481008773228775" LOG_CI_START="-1.1285578016194289" LOG_EFFECT_SIZE="-0.49022846214827565" NO="1" P_CHI2="1.0" P_Z="0.1322658975847349" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.0" Z="1.5052263316035446">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="1.4063741568417323" CI_START="0.0743776064822415" EFFECT_SIZE="0.3234234741084335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.14810087732287758" LOG_CI_START="-1.1285578016194289" LOG_EFFECT_SIZE="-0.49022846214827565" ORDER="137526" O_E="-2.0071942446043165" SE="0.7499156275730922" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="1.7781778330854239" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03189331701905765" CI_END="1.2911136050039258" CI_START="0.13293806557987434" DF="1" EFFECT_SIZE="0.41429234254699887" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.1109644574915427" LOG_CI_START="-0.876350645060137" LOG_EFFECT_SIZE="-0.3826930937842972" NO="2" P_CHI2="0.858262045374238" P_Z="0.12866112981435565" STUDIES="2" TAU2="0.0" TOTAL_1="176" TOTAL_2="141" WEIGHT="100.00000000000001" Z="1.5194028309926935">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="2.5810168578512265" CI_START="0.049525736396847195" EFFECT_SIZE="0.357528684915992" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41179084113738107" LOG_CI_START="-1.3051690582283941" LOG_EFFECT_SIZE="-0.4466891085455066" ORDER="137527" O_E="-1.011173184357542" SE="1.0085507439760297" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="0.9831153834149996" WEIGHT="33.066730547391984"/>
<DICH_DATA CI_END="1.7878118316980973" CI_START="0.11105121385033667" EFFECT_SIZE="0.4455767880467603" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2523218071021814" LOG_CI_START="-0.9544766900140039" LOG_EFFECT_SIZE="-0.3510774414559112" ORDER="137528" O_E="-1.608695652173913" SE="0.7088794109549513" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="1.9900100727167356" WEIGHT="66.93326945260803"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5620963646721835" CI_START="0.0265488253390698" DF="0" EFFECT_SIZE="0.12215972417048054" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="-0.2501892234740361" LOG_CI_START="-1.5759546896501495" LOG_EFFECT_SIZE="-0.9130719565620927" NO="3" P_CHI2="1.0" P_Z="0.006940088298787936" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="2.699705484586058">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="0.5620963646721837" CI_START="0.0265488253390698" EFFECT_SIZE="0.12215972417048054" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="-0.25018922347403594" LOG_CI_START="-1.5759546896501495" LOG_EFFECT_SIZE="-0.9130719565620927" ORDER="137529" O_E="-3.466666666666667" SE="0.7787611974767475" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="1.648888888888889" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2071179976933362" CI_END="3.8039176920708018" CI_START="0.3469281767754384" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1487759701151294" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.5802311112448206" LOG_CI_START="-0.45976042624284974" LOG_EFFECT_SIZE="0.060235342500985445" METHOD="PETO" NO="3" P_CHI2="0.8769253182649316" P_Q="0.5766610805997145" P_Z="0.8203937416203247" Q="0.3116638510702194" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="264" TOTAL_2="238" WEIGHT="200.0" Z="0.22703858183993345">
<NAME>Withdrawals: concurrent illness</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14817657729317607" CI_END="3.803650025545876" CI_START="0.22734719989950194" DF="2" EFFECT_SIZE="0.9299189118979805" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.580200550598073" LOG_CI_START="-0.643310390373251" LOG_EFFECT_SIZE="-0.03155491988758899" NO="2" P_CHI2="0.9285897237831303" P_Z="0.9194736363524757" STUDIES="3" TAU2="0.0" TOTAL_1="210" TOTAL_2="184" WEIGHT="100.0" Z="0.10109677722313172">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="21.10788006974666" CI_START="0.07658775155363393" EFFECT_SIZE="1.2714578540422246" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.324444617947989" LOG_CI_START="-1.115840680210821" LOG_EFFECT_SIZE="0.10430196886858403" ORDER="137530" O_E="0.11688311688311692" SE="1.4334356637455283" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="0.4866801004873459" WEIGHT="25.13821912958143"/>
<DICH_DATA CI_END="7.137467741619806" CI_START="0.13695700779217398" EFFECT_SIZE="0.98869925918118" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.853544158428241" LOG_CI_START="-0.8634157409375341" LOG_EFFECT_SIZE="-0.004935791254646541" ORDER="137531" O_E="-0.011173184357541999" SE="1.0085507439760297" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="0.9831153834149996" WEIGHT="50.780317323846084"/>
<DICH_DATA CI_END="10.402115681306277" CI_START="0.033409370098917625" EFFECT_SIZE="0.5895151674117605" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0171216792286246" LOG_CI_START="-1.4761317124834814" LOG_EFFECT_SIZE="-0.22950501662742845" ORDER="137532" O_E="-0.24637681159420288" SE="1.464549384095026" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="0.46622113676050997" WEIGHT="24.08146354657248"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7472775693299407" CI_END="19.336014266197672" CI_START="0.20516280019333039" DF="1" EFFECT_SIZE="1.9917406536573228" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="1.2863669578241204" LOG_CI_START="-0.6879013820365214" LOG_EFFECT_SIZE="0.2992327878937994" NO="3" P_CHI2="0.38733957148158227" P_Z="0.5524255340137152" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="54" WEIGHT="100.0" Z="0.5941294558841566">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="15.878831772982613" CI_START="0.06011409426640231" EFFECT_SIZE="0.9770064431934014" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008185476370357" LOG_CI_START="-1.2210236919822675" LOG_EFFECT_SIZE="-0.010102572172615823" ORDER="137533" O_E="-0.011494252873563315" SE="1.4226021198648098" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="0.49412075571409697" WEIGHT="66.45392899880335"/>
<DICH_DATA CI_END="413.3852242568678" CI_START="0.16131764544996868" EFFECT_SIZE="8.166169912567655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.616354949460138" LOG_CI_START="-0.7923181254664801" LOG_EFFECT_SIZE="0.9120184119968291" ORDER="137534" O_E="0.5238095238095238" SE="2.002271437415744" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.24943310657596368" WEIGHT="33.546071001196644"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.694421854018585" CI_END="4.615318541292303" CI_START="2.038856417600922" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.067567737994768" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="26" I2="0.0" I2_Q="21.927427162174688" ID="CMP-002.04" LOG_CI_END="0.6642016806493365" LOG_CI_START="0.3093866425318174" LOG_EFFECT_SIZE="0.4867941615905769" METHOD="PETO" NO="4" P_CHI2="0.6814175844962571" P_Q="0.27779853647776065" P_Z="7.531454659976116E-8" Q="2.561719086873773" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="425" TOTAL_2="364" WEIGHT="300.0" Z="5.378007818743538">
<NAME>Withdrawals: adverse reactions</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.335079471598432" CI_START="0.6033662535016661" DF="0" EFFECT_SIZE="1.9550890430907897" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.8017520673426144" LOG_CI_START="-0.21941898373321767" LOG_EFFECT_SIZE="0.2911665418046983" NO="1" P_CHI2="1.0" P_Z="0.2636997684535217" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.0" Z="1.1176892154141307">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="6.335079471598432" CI_START="0.6033662535016661" EFFECT_SIZE="1.9550890430907897" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.8017520673426144" LOG_CI_START="-0.21941898373321767" LOG_EFFECT_SIZE="0.2911665418046983" ORDER="137535" O_E="1.8633093525179856" SE="0.5998409302801705" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="2.7792512314827524" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7035313740737124" CI_END="4.4672749486526895" CI_START="1.5116564099429757" DF="3" EFFECT_SIZE="2.598650575030917" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="17" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.6500426829414948" LOG_CI_START="0.17945308995961817" LOG_EFFECT_SIZE="0.41474788645055644" NO="2" P_CHI2="0.4396275756933946" P_Z="5.50749283554598E-4" STUDIES="4" TAU2="0.0" TOTAL_1="220" TOTAL_2="195" WEIGHT="99.99999999999999" Z="3.45477644312676">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="11.028394479003683" CI_START="1.0147467457160175" EFFECT_SIZE="3.3452993002183646" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="1.0425122921626517" LOG_CI_START="0.006357667212932402" LOG_EFFECT_SIZE="0.5244349796877921" ORDER="137536" O_E="3.2597402597402594" SE="0.6086423557435788" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="2.699452290703145" WEIGHT="20.626972875902972"/>
<DICH_DATA CI_END="7.502895371046411" CI_START="0.0029278971387777363" EFFECT_SIZE="0.14821506633752016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8752288901934647" LOG_CI_START="-2.5334441847331535" LOG_EFFECT_SIZE="-0.8291076472698444" ORDER="137537" O_E="-0.47619047619047616" SE="2.002271437415744" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.24943310657596368" WEIGHT="1.9059606800290778"/>
<DICH_DATA CI_END="4.8745077778711545" CI_START="0.9524320818783593" EFFECT_SIZE="2.154678071316009" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6879307676966776" LOG_CI_START="-0.021165984174258287" LOG_EFFECT_SIZE="0.3333823917612096" ORDER="137538" O_E="4.424581005586592" SE="0.4165269421345194" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="5.76386504790737" WEIGHT="44.04267058655151"/>
<DICH_DATA CI_END="8.554341233415881" CI_START="1.3128423122089492" EFFECT_SIZE="3.3511939848809202" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="0.9321865703109895" LOG_CI_START="0.11821256535059507" LOG_EFFECT_SIZE="0.5251995678307924" ORDER="137539" O_E="5.289855072463768" SE="0.4781323597500429" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="4.3742512537236085" WEIGHT="33.42439585751643"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.42917139307109864" CI_END="10.299184667387541" CI_START="2.3787201743424853" DF="3" EFFECT_SIZE="4.949634163005741" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="1.0128028452420614" LOG_CI_START="0.3763433559142323" LOG_EFFECT_SIZE="0.6945731005781469" NO="3" P_CHI2="0.9341526014122474" P_Z="1.887093746913457E-5" STUDIES="4" TAU2="0.0" TOTAL_1="118" TOTAL_2="117" WEIGHT="100.00000000000001" Z="4.277847324426593">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="21.45662210174369" CI_START="1.4132844109935525" EFFECT_SIZE="5.506751268122983" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.331561352390343" LOG_CI_START="0.1502295685688653" LOG_EFFECT_SIZE="0.7408954604796042" ORDER="137540" O_E="3.5428571428571427" SE="0.6939201375033761" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="2.076734693877551" WEIGHT="29.02670601147842"/>
<DICH_DATA CI_END="13.66835483010148" CI_START="1.99841571063976" EFFECT_SIZE="5.226380681798222" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="1.135716244545429" LOG_CI_START="0.30068583527011983" LOG_EFFECT_SIZE="0.7182010399077744" ORDER="137541" O_E="6.873563218390805" SE="0.4905009958755062" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="4.156427533359756" WEIGHT="58.094758287869055"/>
<DICH_DATA CI_END="320.39687109040506" CI_START="0.12210257817129111" EFFECT_SIZE="6.254700951936332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.505688266229907" LOG_CI_START="-0.9132751659179834" LOG_EFFECT_SIZE="0.7962065501559619" ORDER="137542" O_E="0.4545454545454546" SE="2.008316044185609" STUDY_ID="STD-Huskisson-1976" TOTAL_1="12" TOTAL_2="10" VAR="0.2479338842975206" WEIGHT="3.4653940106094123"/>
<DICH_DATA CI_END="25.451798329804127" CI_START="0.21442040005119395" EFFECT_SIZE="2.3361046166426087" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4057184733964898" LOG_CI_START="-0.6687338980455168" LOG_EFFECT_SIZE="0.3684922876754864" ORDER="137543" O_E="0.5714285714285714" SE="1.2185435916898848" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.673469387755102" WEIGHT="9.413141690043119"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9523875731737754" CI_END="3.7122296508486508" CI_START="0.36718897315411825" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1675143654822355" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.5696348352761528" LOG_CI_START="-0.43511036932870606" LOG_EFFECT_SIZE="0.06726223297372337" METHOD="PETO" NO="5" P_CHI2="0.7445159511526611" P_Q="0.6494489115203326" P_Z="0.7929992882387183" Q="0.8632622710199322" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="303" TOTAL_2="243" WEIGHT="300.0" Z="0.2624178817555768">
<NAME>Withdrawals:Gastrointestinal adverse reactions</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.307902433272684" CI_START="0.032839078356538036" DF="0" EFFECT_SIZE="0.5818092605809836" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="1.0131702991986358" LOG_CI_START="-1.4836090400509696" LOG_EFFECT_SIZE="-0.23521937042616683" NO="1" P_CHI2="1.0" P_Z="0.7119093861949454" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.0" Z="0.3692929425153211">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="10.307902433272684" CI_START="0.032839078356538036" EFFECT_SIZE="0.5818092605809836" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0131702991986358" LOG_CI_START="-1.4836090400509696" LOG_EFFECT_SIZE="-0.23521937042616683" ORDER="137544" O_E="-0.2517985611510791" SE="1.4666205431322752" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="0.4649052731540135" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7123139393495218" CI_END="5.419514963635834" CI_START="0.09523318318874373" DF="1" EFFECT_SIZE="0.7184132942297694" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.733960419740873" LOG_CI_START="-1.0212116990448454" LOG_EFFECT_SIZE="-0.14362563965198621" NO="2" P_CHI2="0.3986771872295961" P_Z="0.7483865953018835" STUDIES="2" TAU2="0.0" TOTAL_1="120" TOTAL_2="95" WEIGHT="100.0" Z="0.32076749392438153">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="8.638977066276796" CI_START="0.003222236711926982" EFFECT_SIZE="0.16684372645218748" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9364623210932227" LOG_CI_START="-2.4918425586071944" LOG_EFFECT_SIZE="-0.7776901187569858" ORDER="137545" O_E="-0.44155844155844154" SE="2.0138032567188744" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="0.24658458424692192" WEIGHT="26.210816452526608"/>
<DICH_DATA CI_END="12.683267107538207" CI_START="0.11480807328666837" EFFECT_SIZE="1.2067068656457693" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.103231138720243" LOG_CI_START="-0.9400275713407383" LOG_EFFECT_SIZE="0.08160178368975227" ORDER="137546" O_E="0.13043478260869557" SE="1.2002202805835565" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="0.6941895602500241" WEIGHT="73.7891835474734"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.37681136280432126" CI_END="10.04290521731452" CI_START="0.39394575412732147" DF="1" EFFECT_SIZE="1.9890600467216113" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="1.0018593639380153" LOG_CI_START="-0.40456357590309977" LOG_EFFECT_SIZE="0.2986478940174577" NO="3" P_CHI2="0.5393150059603835" P_Z="0.4051945331703729" STUDIES="2" TAU2="0.0" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.00000000000001" Z="0.8323799331644557">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="20.871009896711318" CI_START="0.39080833932146053" EFFECT_SIZE="2.855970013444735" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.319543464013113" LOG_CI_START="-0.40803617759745203" LOG_EFFECT_SIZE="0.45575364320783046" ORDER="137547" O_E="1.019047619047619" SE="1.0147888331391912" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="0.9710657596371883" WEIGHT="66.2759143264686"/>
<DICH_DATA CI_END="15.878831772982613" CI_START="0.06011409426640231" EFFECT_SIZE="0.9770064431934014" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008185476370357" LOG_CI_START="-1.2210236919822675" LOG_EFFECT_SIZE="-0.010102572172615823" ORDER="137548" O_E="-0.011494252873563315" SE="1.4226021198648098" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="0.49412075571409697" WEIGHT="33.72408567353142"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.657742949345479" CI_END="7.4067180227940925" CI_START="0.9179580821242819" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.6075000807362247" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.869625811173048" LOG_CI_START="-0.0371771500817241" LOG_EFFECT_SIZE="0.416224330545662" METHOD="PETO" NO="6" P_CHI2="0.4543018437552637" P_Q="0.8048412184633407" P_Z="0.07197841691133132" Q="0.4342208305267931" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="247" TOTAL_2="178" WEIGHT="300.0" Z="1.7992545949121406">
<NAME>Withdrawals:Mucosal / cutaneous adverse reactions</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.32151611120986" CI_START="0.22183722918161453" DF="0" EFFECT_SIZE="1.7190719073410026" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="1.1245536543585148" LOG_CI_START="-0.6539655678741646" LOG_EFFECT_SIZE="0.23529404324217515" NO="1" P_CHI2="1.0" P_Z="0.6040414240164085" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.0" Z="0.5185975442565557">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="13.32151611120986" CI_START="0.22183722918161453" EFFECT_SIZE="1.7190719073410026" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1245536543585148" LOG_CI_START="-0.6539655678741646" LOG_EFFECT_SIZE="0.23529404324217515" ORDER="137549" O_E="0.49640287769784175" SE="1.044710994951612" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="0.9162366697195886" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.618081750359643" CI_START="0.34638488996474615" DF="0" EFFECT_SIZE="2.171888060796238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="1.1341159369522904" LOG_CI_START="-0.46044106107749294" LOG_EFFECT_SIZE="0.3368374379373988" NO="2" P_CHI2="1.0" P_Z="0.40764021326745203" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="52" WEIGHT="100.00000000000001" Z="0.828053494252974">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="13.618081750359643" CI_START="0.34638488996474615" EFFECT_SIZE="2.171888060796238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1341159369522904" LOG_CI_START="-0.46044106107749294" LOG_EFFECT_SIZE="0.3368374379373988" ORDER="137550" O_E="0.8840579710144927" SE="0.9366506738271346" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="1.1398421174475701" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.223522118818685" CI_END="19.64142739537535" CI_START="0.7732243850997491" DF="2" EFFECT_SIZE="3.897079755441306" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="37.956064010724575" ID="CMP-002.06.03" LOG_CI_END="1.2931730459463078" LOG_CI_START="-0.11169445812606724" LOG_EFFECT_SIZE="0.5907392939101203" NO="3" P_CHI2="0.19953605583081202" P_Z="0.09928931826196055" STUDIES="3" TAU2="0.0" TOTAL_1="74" TOTAL_2="74" WEIGHT="100.0" Z="1.648308807713456">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="58.449169883811955" CI_START="1.094457006635304" EFFECT_SIZE="7.9981312511958205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7667783475348158" LOG_CI_START="0.039198705924250864" LOG_EFFECT_SIZE="0.9029885267295333" ORDER="137551" O_E="2.019047619047619" SE="1.0147888331391912" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="0.9710657596371883" WEIGHT="66.12939947706039"/>
<DICH_DATA CI_END="320.39687109040506" CI_START="0.12210257817129111" EFFECT_SIZE="6.254700951936332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.505688266229907" LOG_CI_START="-0.9132751659179834" LOG_EFFECT_SIZE="0.7962065501559619" ORDER="137552" O_E="0.4545454545454546" SE="2.008316044185609" STUDY_ID="STD-Huskisson-1976" TOTAL_1="12" TOTAL_2="10" VAR="0.2479338842975206" WEIGHT="16.884251880877578"/>
<DICH_DATA CI_END="7.502895371046411" CI_START="0.0029278971387777363" EFFECT_SIZE="0.14821506633752016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8752288901934647" LOG_CI_START="-2.5334441847331535" LOG_EFFECT_SIZE="-0.8291076472698444" ORDER="137553" O_E="-0.47619047619047616" SE="2.002271437415744" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.24943310657596368" WEIGHT="16.986348642062023"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1180812482145222" CI_END="22.463434863681513" CI_START="1.5089114305693323" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.821969910233022" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="1.351476164582904" LOG_CI_START="0.1786637484940196" LOG_EFFECT_SIZE="0.7650699565384619" METHOD="PETO" NO="7" P_CHI2="0.9895826424845755" P_Q="0.9790463613337417" P_Z="0.010554356849309287" Q="0.042352580363507794" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="217" TOTAL_2="158" WEIGHT="300.0" Z="2.5571174723228127">
<NAME>Withdrawals: Renal abnormality</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.348631843458904" CI_START="0.479766945416743" DF="0" EFFECT_SIZE="5.059141245478195" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="1.7271232861699508" LOG_CI_START="-0.3189696769968309" LOG_EFFECT_SIZE="0.70407680458656" NO="1" P_CHI2="1.0" P_Z="0.17737606546694895" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.0" Z="1.3488782808811404">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="53.348631843458904" CI_START="0.479766945416743" EFFECT_SIZE="5.059141245478195" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7271232861699508" LOG_CI_START="-0.3189696769968309" LOG_EFFECT_SIZE="0.70407680458656" ORDER="137554" O_E="1.1223021582733812" SE="1.2018851348876827" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="0.6922677060103558" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07572866785101595" CI_END="36.171471625234524" CI_START="0.9579283091086414" DF="1" EFFECT_SIZE="5.886397595468056" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="1.5583661782589222" LOG_CI_START="-0.018666992094267008" LOG_EFFECT_SIZE="0.7698495930823277" NO="2" P_CHI2="0.7831714886751964" P_Z="0.05567580345592172" STUDIES="2" TAU2="0.0" TOTAL_1="120" TOTAL_2="95" WEIGHT="100.0" Z="1.9135646660066803">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="498.5419495776146" CI_START="0.18595027629318284" EFFECT_SIZE="9.628292333934375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.697701707689926" LOG_CI_START="-0.730603172010491" LOG_EFFECT_SIZE="0.9835492678397175" ORDER="137555" O_E="0.5584415584415585" SE="2.0138032567188744" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="0.24658458424692192" WEIGHT="21.160346867763174"/>
<DICH_DATA CI_END="39.860739942032886" CI_START="0.6674842393221734" EFFECT_SIZE="5.1581407191959" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.60054535632531" LOG_CI_START="-0.17555898442963458" LOG_EFFECT_SIZE="0.7124931859478377" ORDER="137556" O_E="1.5072463768115942" SE="1.0432924816177345" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="0.9187298871457108" WEIGHT="78.83965313223683"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="413.3852242568678" CI_START="0.16131764544996868" DF="0" EFFECT_SIZE="8.166169912567655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="2.616354949460138" LOG_CI_START="-0.7923181254664801" LOG_EFFECT_SIZE="0.9120184119968291" NO="3" P_CHI2="1.0" P_Z="0.29426611955214055" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="1.0488088481701519">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="413.3852242568678" CI_START="0.16131764544996868" EFFECT_SIZE="8.166169912567655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.616354949460138" LOG_CI_START="-0.7923181254664801" LOG_EFFECT_SIZE="0.9120184119968291" ORDER="137557" O_E="0.5238095238095238" SE="2.002271437415744" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.24943310657596368" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4101176658969816" CI_END="12.624555427067769" CI_START="1.9445366558543" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.954685740972642" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="1.1012160934068729" LOG_CI_START="0.2888161343105317" LOG_EFFECT_SIZE="0.6950161138587023" METHOD="PETO" NO="8" P_CHI2="0.6370295365599158" P_Q="0.9217503925544422" P_Z="7.978582311191036E-4" Q="0.16296169265794508" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="273" TOTAL_2="211" WEIGHT="300.0" Z="3.3535367317183833">
<NAME>Withdrawals: Hematological abnormality</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.348631843458904" CI_START="0.479766945416743" DF="0" EFFECT_SIZE="5.059141245478195" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="1.7271232861699508" LOG_CI_START="-0.3189696769968309" LOG_EFFECT_SIZE="0.70407680458656" NO="1" P_CHI2="1.0" P_Z="0.17737606546694895" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.0" Z="1.3488782808811404">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="53.348631843458904" CI_START="0.479766945416743" EFFECT_SIZE="5.059141245478195" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7271232861699508" LOG_CI_START="-0.3189696769968309" LOG_EFFECT_SIZE="0.70407680458656" ORDER="137558" O_E="1.1223021582733812" SE="1.2018851348876827" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="0.6922677060103558" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06893652839217201" CI_END="21.682743098631484" CI_START="1.5768221698304912" DF="1" EFFECT_SIZE="5.847207027347434" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="1.3361142242334576" LOG_CI_START="0.19778271741507092" LOG_EFFECT_SIZE="0.7669484708242643" NO="2" P_CHI2="0.7928915373581803" P_Z="0.008265116345971482" STUDIES="2" TAU2="0.0" TOTAL_1="120" TOTAL_2="95" WEIGHT="100.0" Z="2.641043266939023">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="498.5419495776146" CI_START="0.18595027629318284" EFFECT_SIZE="9.628292333934375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.697701707689926" LOG_CI_START="-0.730603172010491" LOG_EFFECT_SIZE="0.9835492678397175" ORDER="137559" O_E="0.5584415584415585" SE="2.0138032567188744" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="0.24658458424692192" WEIGHT="11.02500104250802"/>
<DICH_DATA CI_END="22.055070454657688" CI_START="1.3699665155577905" EFFECT_SIZE="5.496790701959551" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.3435084494651488" LOG_CI_START="0.13670995234896344" LOG_EFFECT_SIZE="0.7401092009070561" ORDER="137560" O_E="3.391304347826087" SE="0.7088794109549513" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="1.9900100727167356" WEIGHT="88.97499895749198"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1782194448468672" CI_END="19.257589993524725" CI_START="0.7530406370075289" DF="2" EFFECT_SIZE="3.8081160481206022" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="37.07168322682124" ID="CMP-002.08.03" LOG_CI_END="1.2846019360593925" LOG_CI_START="-0.12318158694414232" LOG_EFFECT_SIZE="0.5807101745576251" NO="3" P_CHI2="0.2041073686952628" P_Z="0.10588501256585689" STUDIES="3" TAU2="0.0" TOTAL_1="66" TOTAL_2="64" WEIGHT="100.0" Z="1.6169688151493666">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="57.05084166049122" CI_START="1.0549970842594132" EFFECT_SIZE="7.758122943493723" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7562620558674793" LOG_CI_START="0.023251259357126294" LOG_EFFECT_SIZE="0.8897566576123028" ORDER="137561" O_E="1.9770114942528734" SE="1.017979120411977" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="0.9649887699828247" WEIGHT="65.98864625238375"/>
<DICH_DATA CI_END="320.39687109040506" CI_START="0.12210257817129111" EFFECT_SIZE="6.254700951936332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.505688266229907" LOG_CI_START="-0.9132751659179834" LOG_EFFECT_SIZE="0.7962065501559619" ORDER="137562" O_E="0.4545454545454546" SE="2.008316044185609" STUDY_ID="STD-Huskisson-1976" TOTAL_1="12" TOTAL_2="10" VAR="0.2479338842975206" WEIGHT="16.954416355725805"/>
<DICH_DATA CI_END="7.502895371046411" CI_START="0.0029278971387777363" EFFECT_SIZE="0.14821506633752016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8752288901934647" LOG_CI_START="-2.5334441847331535" LOG_EFFECT_SIZE="-0.8291076472698444" ORDER="137563" O_E="-0.47619047619047616" SE="2.002271437415744" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.24943310657596368" WEIGHT="17.056937391890436"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.006976933021478782" CI_END="69.68263128126219" CI_START="0.7382925785729274" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.172598520089466" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="1.8431245416746436" LOG_CI_START="-0.1317714971484749" LOG_EFFECT_SIZE="0.8556765222630843" METHOD="PETO" NO="9" P_CHI2="0.933431684926588" P_Q="1.0" P_Z="0.0894297231051952" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="63" WEIGHT="100.0" Z="1.6984136208522118">
<NAME>Withdrawals: Impaired or loss of taste</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.006976933021478782" CI_END="69.68263128126219" CI_START="0.7382925785729274" DF="1" EFFECT_SIZE="7.172598520089466" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="1.8431245416746436" LOG_CI_START="-0.1317714971484749" LOG_EFFECT_SIZE="0.8556765222630843" NO="3" P_CHI2="0.933431684926588" P_Z="0.0894297231051952" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="63" WEIGHT="100.0" Z="1.6984136208522118">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="124.48581813994842" CI_START="0.47401235321988" EFFECT_SIZE="7.681654483183878" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.09511987790257" LOG_CI_START="-0.32421034004465055" LOG_EFFECT_SIZE="0.8854547689289598" ORDER="137564" O_E="1.0095238095238095" SE="1.4211265458999207" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="0.4951473922902495" WEIGHT="66.63435183886838"/>
<DICH_DATA CI_END="320.39687109040506" CI_START="0.12210257817129111" EFFECT_SIZE="6.254700951936332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.505688266229907" LOG_CI_START="-0.9132751659179834" LOG_EFFECT_SIZE="0.7962065501559619" ORDER="137565" O_E="0.4545454545454546" SE="2.008316044185609" STUDY_ID="STD-Huskisson-1976" TOTAL_1="12" TOTAL_2="10" VAR="0.2479338842975206" WEIGHT="33.36564816113161"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Adverse reactions not requiring withdrawal</NAME>
<DICH_OUTCOME CHI2="1.3916803099159107" CI_END="1.2338117964002628" CI_START="0.5657507294153226" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8354818512539205" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.0912489181911908" LOG_CI_START="-0.24737487744244213" LOG_EFFECT_SIZE="-0.07806297962562567" METHOD="PETO" NO="1" P_CHI2="0.9858247274152853" P_Q="0.6449342532624033" P_Z="0.3661749767935033" Q="0.8772138720170048" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="412" TOTAL_2="354" WEIGHT="300.0" Z="0.9036614116607816">
<NAME>Adverse reactions: Gastrointestinal</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.909957588983575" CI_START="0.16731576956025093" DF="0" EFFECT_SIZE="0.5653017104416262" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.2810237237530148" LOG_CI_START="-0.7764631247265114" LOG_EFFECT_SIZE="-0.2477197004867483" NO="1" P_CHI2="1.0" P_Z="0.3584849967521846" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="52" WEIGHT="100.0" Z="0.918255753086987">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="1.909957588983575" CI_START="0.16731576956025093" EFFECT_SIZE="0.5653017104416262" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.2810237237530148" LOG_CI_START="-0.7764631247265114" LOG_EFFECT_SIZE="-0.2477197004867483" ORDER="137566" O_E="-1.4782608695652177" SE="0.6211730094411969" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="2.591641024933423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29332464149283854" CI_END="1.3438615732925219" CI_START="0.44076980314308467" DF="3" EFFECT_SIZE="0.7696321206340734" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.12835453579267644" LOG_CI_START="-0.35578816637393473" LOG_EFFECT_SIZE="-0.11371681529062916" NO="2" P_CHI2="0.9612790088996623" P_Z="0.35719464018497427" STUDIES="4" TAU2="0.0" TOTAL_1="220" TOTAL_2="195" WEIGHT="100.00000000000001" Z="0.9207238337324993">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="2.9473283419581953" CI_START="0.3256569499849779" EFFECT_SIZE="0.9797029950175654" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.46942852036211935" LOG_CI_START="-0.4872396489257435" LOG_EFFECT_SIZE="-0.008905564281812108" ORDER="137567" O_E="-0.06493506493506462" SE="0.5619516182235031" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="3.1666651871709974" WEIGHT="25.610858183307375"/>
<DICH_DATA CI_END="4.856761076069554" CI_START="0.09594231686250203" EFFECT_SIZE="0.6826191544966574" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6863467392776857" LOG_CI_START="-1.0179897981856236" LOG_EFFECT_SIZE="-0.1658215294539689" ORDER="137568" O_E="-0.38095238095238093" SE="1.001135718707872" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.9977324263038547" WEIGHT="8.069303877933265"/>
<DICH_DATA CI_END="1.5869907607013454" CI_START="0.2856128676278263" EFFECT_SIZE="0.6732495689287715" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.2005743983439454" LOG_CI_START="-0.5442222303206763" LOG_EFFECT_SIZE="-0.17182391598836547" ORDER="137569" O_E="-2.067039106145252" SE="0.43749722648037065" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="5.224556037576855" WEIGHT="42.254345136076985"/>
<DICH_DATA CI_END="2.441690257744855" CI_START="0.2516425449262805" EFFECT_SIZE="0.7838578636338485" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3876905703852223" LOG_CI_START="-0.5992159313321608" LOG_EFFECT_SIZE="-0.10576268047346929" ORDER="137570" O_E="-0.72463768115942" SE="0.5797137643747629" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="2.975587843442079" WEIGHT="24.065492802682385"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.221141796406067" CI_END="1.8717765140374751" CI_START="0.5524420532810844" DF="2" EFFECT_SIZE="1.0168815371999698" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.27225399369996317" LOG_CI_START="-0.2577132692447982" LOG_EFFECT_SIZE="0.007270362227582533" NO="3" P_CHI2="0.8953228534667922" P_Z="0.9571139667545765" STUDIES="3" TAU2="0.0" TOTAL_1="106" TOTAL_2="107" WEIGHT="100.0" Z="0.053775578670440714">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="2.54775319930097" CI_START="0.4940688649657004" EFFECT_SIZE="1.1219472052602841" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.40615735562052885" LOG_CI_START="-0.3062125134443944" LOG_EFFECT_SIZE="0.04997242108806723" ORDER="137571" O_E="0.6571428571428584" SE="0.41844958737645904" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="5.711020408163266" WEIGHT="55.34609735077349"/>
<DICH_DATA CI_END="2.726191456389003" CI_START="0.34638035450526783" EFFECT_SIZE="0.9717505663045716" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.4355563524280401" LOG_CI_START="-0.46044674763593413" LOG_EFFECT_SIZE="-0.012445197603946967" ORDER="137572" O_E="-0.1034482758620694" SE="0.5263166562644551" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="3.609988109393579" WEIGHT="34.984773133018706"/>
<DICH_DATA CI_END="4.856761076069554" CI_START="0.09594231686250203" EFFECT_SIZE="0.6826191544966574" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6863467392776857" LOG_CI_START="-1.0179897981856236" LOG_EFFECT_SIZE="-0.1658215294539689" ORDER="137573" O_E="-0.38095238095238093" SE="1.001135718707872" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.9977324263038547" WEIGHT="9.669129516207803"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.591533568534821" CI_END="3.3801709089741485" CI_START="1.5030654934172274" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.254022682923086" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="40" I2="33.90947633121325" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.5289386597296851" LOG_CI_START="0.17697790461219612" LOG_EFFECT_SIZE="0.3529582821709406" METHOD="PETO" NO="2" P_CHI2="0.1574552064960686" P_Q="0.641918150039579" P_Z="8.457996157700918E-5" Q="0.8865890289207072" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="413" TOTAL_2="354" WEIGHT="300.0" Z="3.9310378276080407">
<NAME>Adverse reactions: Mucosal / cutaneous</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.33287459716701" CI_START="0.5889777471712269" DF="0" EFFECT_SIZE="2.2153730403026417" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.9207948461040434" LOG_CI_START="-0.22990111346978992" LOG_EFFECT_SIZE="0.34544686631712673" NO="1" P_CHI2="1.0" P_Z="0.2392795864499192" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.00000000000001" Z="1.1767894219504262">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="8.332874597167013" CI_START="0.5889777471712268" EFFECT_SIZE="2.2153730403026417" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.9207948461040436" LOG_CI_START="-0.22990111346979" LOG_EFFECT_SIZE="0.34544686631712673" ORDER="137574" O_E="1.7410071942446042" SE="0.6759245026905342" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="2.188787599885684" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.606705368755528" CI_END="4.593198522192884" CI_START="1.5415129726822843" DF="3" EFFECT_SIZE="2.660916215904858" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="20" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.6621152164237339" LOG_CI_START="0.1879471839056182" LOG_EFFECT_SIZE="0.4250312001646761" NO="2" P_CHI2="0.4563152682205842" P_Z="4.4188538034732545E-4" STUDIES="4" TAU2="0.0" TOTAL_1="220" TOTAL_2="195" WEIGHT="100.0" Z="3.513715761075787">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="66.95601332841227" CI_START="1.7807059117668693" EFFECT_SIZE="10.919201837233569" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.8257895871444692" LOG_CI_START="0.2505922005171567" LOG_EFFECT_SIZE="1.0381908938308126" ORDER="137575" O_E="2.792207792207792" SE="0.925278742257701" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="1.16803224116963" WEIGHT="9.061384882895466"/>
<DICH_DATA CI_END="25.451798329804127" CI_START="0.21442040005119395" EFFECT_SIZE="2.3361046166426087" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4057184733964898" LOG_CI_START="-0.6687338980455168" LOG_EFFECT_SIZE="0.3684922876754864" ORDER="137576" O_E="0.5714285714285714" SE="1.2185435916898848" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.673469387755102" WEIGHT="5.224654863281884"/>
<DICH_DATA CI_END="4.567251117190212" CI_START="1.2417350938514058" EFFECT_SIZE="2.38145249682775" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.6596548906987069" LOG_CI_START="0.09402895530149766" LOG_EFFECT_SIZE="0.3768419230001022" ORDER="137577" O_E="7.860335195530727" SE="0.332251474345857" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="9.058706032895355" WEIGHT="70.27581860486592"/>
<DICH_DATA CI_END="8.07297843773555" CI_START="0.5014588442714364" EFFECT_SIZE="2.012030426513251" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9070337925199617" LOG_CI_START="-0.29976470459622345" LOG_EFFECT_SIZE="0.3036345439618692" ORDER="137578" O_E="1.391304347826087" SE="0.7088794109549513" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="1.9900100727167356" WEIGHT="15.438141648956726"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.098239170858579" CI_END="3.4545177881026854" CI_START="0.8872961566038569" DF="2" EFFECT_SIZE="1.7507656485958278" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" I2="71.82399815138821" ID="CMP-003.02.03" LOG_CI_END="0.5383874333073491" LOG_CI_START="-0.05193139965918554" LOG_EFFECT_SIZE="0.2432280168240818" NO="3" P_CHI2="0.028749984353332758" P_Z="0.10628450795990074" STUDIES="3" TAU2="0.0" TOTAL_1="106" TOTAL_2="107" WEIGHT="100.0" Z="1.6151209359547165">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="2.3200033172148435" CI_START="0.45577223533131667" EFFECT_SIZE="1.0282962111488494" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.36548860585946513" LOG_CI_START="-0.34125213463977805" LOG_EFFECT_SIZE="0.012118235609843564" ORDER="137579" O_E="0.16190476190476133" SE="0.4151430093923428" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="5.802358276643991" WEIGHT="69.76747783919896"/>
<DICH_DATA CI_END="34.88912746686087" CI_START="2.2433372779705083" EFFECT_SIZE="8.84692490316685" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.5426901084258717" LOG_CI_START="0.35089457315928557" LOG_EFFECT_SIZE="0.9467923407925787" ORDER="137580" O_E="4.448275862068965" SE="0.7000665968986379" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="2.0404280618311534" WEIGHT="24.53407955853103"/>
<DICH_DATA CI_END="19.05868467429689" CI_START="0.06414777016023977" EFFECT_SIZE="1.1056998345135451" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2800929247175128" LOG_CI_START="-1.1928184355312133" LOG_EFFECT_SIZE="0.04363724459314978" ORDER="137581" O_E="0.04761904761904767" SE="1.452600374118757" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.473922902494331" WEIGHT="5.6984426022700045"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2207259967949355" CI_END="4.8312492615057465" CI_START="0.5340717495572925" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6063106006123946" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.6840594448770954" LOG_CI_START="-0.2724003940133873" LOG_EFFECT_SIZE="0.20582952543185407" METHOD="PETO" NO="3" P_CHI2="0.5431539475903113" P_Q="0.5431539475903113" P_Z="0.39891202939679793" Q="1.2207259967949353" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="231" WEIGHT="100.0" Z="0.843565909195687">
<NAME>Adverse reactions: Renal</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.137467741619806" CI_START="0.13695700779217398" DF="0" EFFECT_SIZE="0.98869925918118" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.853544158428241" LOG_CI_START="-0.8634157409375341" LOG_EFFECT_SIZE="-0.004935791254646541" NO="1" P_CHI2="1.0" P_Z="0.9910090498661969" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="89" WEIGHT="31.03224346488854" Z="0.01126872339638032">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="7.137467741619806" CI_START="0.13695700779217398" EFFECT_SIZE="0.98869925918118" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.853544158428241" LOG_CI_START="-0.8634157409375341" LOG_EFFECT_SIZE="-0.004935791254646541" ORDER="137582" O_E="-0.011173184357541999" SE="1.0085507439760297" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="0.9831153834149996" WEIGHT="31.03224346488854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.137467741619806" CI_START="0.13695700779217398" DF="0" EFFECT_SIZE="0.98869925918118" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.853544158428241" LOG_CI_START="-0.8634157409375341" LOG_EFFECT_SIZE="-0.004935791254646541" NO="2" P_CHI2="1.0" P_Z="0.9910090498661969" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="89" WEIGHT="31.03224346488854" Z="0.01126872339638032">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="7.137467741619806" CI_START="0.13695700779217398" EFFECT_SIZE="0.98869925918118" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.853544158428241" LOG_CI_START="-0.8634157409375341" LOG_EFFECT_SIZE="-0.004935791254646541" ORDER="137583" O_E="-0.011173184357541999" SE="1.0085507439760297" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="0.9831153834149996" WEIGHT="31.03224346488854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.23748598055316" CI_START="0.5945688426769815" DF="0" EFFECT_SIZE="3.5534697776716926" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="1.3271031051875006" LOG_CI_START="-0.2257978529649147" LOG_EFFECT_SIZE="0.5506526261112928" NO="3" P_CHI2="1.0" P_Z="0.16453155663069677" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="37.93551307022292" Z="1.389991176841822">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="21.23748598055316" CI_START="0.5945688426769815" EFFECT_SIZE="3.5534697776716926" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3271031051875006" LOG_CI_START="-0.2257978529649147" LOG_EFFECT_SIZE="0.5506526261112928" ORDER="137584" O_E="1.5238095238095237" SE="0.9121817098024456" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="1.2018140589569162" WEIGHT="37.93551307022292"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1320225703497897" CI_START="0.008211096294467106" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13231115836209506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.32879179797483643" LOG_CI_START="-2.0855988547134143" LOG_EFFECT_SIZE="-0.8784035283692889" METHOD="PETO" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.15382560695515188" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="89" WEIGHT="100.0" Z="1.4261480656245848">
<NAME>Adverse reactions: Liver</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1320225703497897" CI_START="0.008211096294467106" DF="0" EFFECT_SIZE="0.13231115836209506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.32879179797483643" LOG_CI_START="-2.0855988547134143" LOG_EFFECT_SIZE="-0.8784035283692889" NO="1" P_CHI2="1.0" P_Z="0.15382560695515188" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="89" WEIGHT="100.0" Z="1.4261480656245848">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="2.1320225703497897" CI_START="0.008211096294467106" EFFECT_SIZE="0.13231115836209506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32879179797483643" LOG_CI_START="-2.0855988547134143" LOG_EFFECT_SIZE="-0.8784035283692889" ORDER="137585" O_E="-1.005586592178771" SE="1.4182250208155596" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="0.4971754938984427" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.52720605673375" CI_START="2.2179261751264585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="6.234905700174203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="1.2437126924286865" LOG_CI_START="0.34594708632675875" LOG_EFFECT_SIZE="0.7948298893777226" METHOD="PETO" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="5.19532622961794E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="3.470478143577763">
<NAME>Adverse reactions: Haematological</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.52720605673375" CI_START="2.2179261751264585" DF="0" EFFECT_SIZE="6.234905700174203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="1.2437126924286865" LOG_CI_START="0.34594708632675875" LOG_EFFECT_SIZE="0.7948298893777226" NO="2" P_CHI2="1.0" P_Z="5.19532622961794E-4" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="3.470478143577763">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="17.52720605673375" CI_START="2.2179261751264585" EFFECT_SIZE="6.234905700174203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.2437126924286865" LOG_CI_START="0.34594708632675875" LOG_EFFECT_SIZE="0.7948298893777226" ORDER="137586" O_E="6.580952380952381" SE="0.5273519610356947" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="3.595827664399093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1474827126785051" CI_END="3.8925739728304505" CI_START="0.1146551918896625" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6680597396936753" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.5902368744673433" LOG_CI_START="-0.940606274488526" LOG_EFFECT_SIZE="-0.17518470001059136" METHOD="PETO" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.700952813645243" P_Q="0.700952813645243" P_Z="0.6537319385280012" Q="0.14748271267850513" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="142" TOTAL_2="142" WEIGHT="200.0" Z="0.4485837793341569">
<NAME>Adverse reactions: Neurological (headache, dizziness, tingling)</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.906032727218978" CI_START="0.051736406234734536" DF="0" EFFECT_SIZE="0.5038060164153496" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.6907304409766049" LOG_CI_START="-1.286203741963311" LOG_EFFECT_SIZE="-0.2977366504933532" NO="1" P_CHI2="1.0" P_Z="0.5549481856296261" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="89" WEIGHT="100.0" Z="0.5903616993224884">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="4.906032727218978" CI_START="0.051736406234734536" EFFECT_SIZE="0.5038060164153496" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6907304409766049" LOG_CI_START="-1.286203741963311" LOG_EFFECT_SIZE="-0.2977366504933532" ORDER="137587" O_E="-0.5083798882681565" SE="1.1612609250409385" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="0.7415498892044567" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.520320017631295" CI_START="0.06290544484914237" DF="0" EFFECT_SIZE="1.019420462694019" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="1.2180184558502989" LOG_CI_START="-1.2013117620969223" LOG_EFFECT_SIZE="0.008353346876688287" NO="2" P_CHI2="1.0" P_Z="0.9892013303574224" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.013534538532380147">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="16.52032001763129" CI_START="0.0629054448491424" EFFECT_SIZE="1.019420462694019" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2180184558502987" LOG_CI_START="-1.201311762096922" LOG_EFFECT_SIZE="0.008353346876688287" ORDER="137588" O_E="0.00952380952380949" SE="1.4211265458999207" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="0.4951473922902495" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.665407733070973" CI_START="0.002622983798241793" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13222426589896694" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.8238267210126976" LOG_CI_START="-2.581204391970042" LOG_EFFECT_SIZE="-0.8786888354786723" METHOD="PETO" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.31174797771339413" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="1.0115610777177464">
<NAME>Adverse reactions: Cardiovascular</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.665407733070973" CI_START="0.002622983798241793" DF="0" EFFECT_SIZE="0.13222426589896694" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.8238267210126976" LOG_CI_START="-2.581204391970042" LOG_EFFECT_SIZE="-0.8786888354786723" NO="1" P_CHI2="1.0" P_Z="0.31174797771339413" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="1.0115610777177464">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="6.665407733070973" CI_START="0.002622983798241793" EFFECT_SIZE="0.13222426589896694" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8238267210126976" LOG_CI_START="-2.581204391970042" LOG_EFFECT_SIZE="-0.8786888354786723" ORDER="137589" O_E="-0.5057471264367817" SE="2.0001321309419073" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="0.24996697053771966" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.609955703662403" CI_END="5.649769796018597" CI_START="2.048980856291171" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.402391828478046" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.7520307525352594" LOG_CI_START="0.3115379007897033" LOG_EFFECT_SIZE="0.5317843266624814" METHOD="PETO" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9185923077273798" P_Q="0.8627573215922015" P_Z="2.219603584470749E-6" Q="0.2952436907597853" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="413" TOTAL_2="354" WEIGHT="300.0" Z="4.732327090762429">
<NAME>Adverse reactions: Impaired or loss of taste</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="39.67818513203223" CI_START="0.6607430096667697" DF="0" EFFECT_SIZE="5.120262050154684" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="1.5985517994405778" LOG_CI_START="-0.17996742279210146" LOG_EFFECT_SIZE="0.7092921883242382" NO="1" P_CHI2="1.0" P_Z="0.11798004075726898" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="52" WEIGHT="100.0" Z="1.5633085392081678">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
<DICH_DATA CI_END="39.67818513203223" CI_START="0.6607430096667697" EFFECT_SIZE="5.120262050154684" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.5985517994405778" LOG_CI_START="-0.17996742279210146" LOG_EFFECT_SIZE="0.7092921883242382" ORDER="137590" O_E="1.4964028776978417" SE="1.044710994951612" STUDY_ID="STD-Williams-1983" TOTAL_1="87" TOTAL_2="52" VAR="0.9162366697195886" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8048217030783644" CI_END="8.672162662585123" CI_START="1.6149928706956922" DF="3" EFFECT_SIZE="3.742389727645739" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.9381274152737169" LOG_CI_START="0.20817060950033858" LOG_EFFECT_SIZE="0.5731490123870278" NO="2" P_CHI2="0.8483134555718229" P_Z="0.0020849476593288226" STUDIES="4" TAU2="0.0" TOTAL_1="220" TOTAL_2="195" WEIGHT="100.0" Z="3.0778572462602134">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="13.61650587072278" CI_START="1.0588759577493512" EFFECT_SIZE="3.797129270259474" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.1340656776393374" LOG_CI_START="0.024845087567151248" LOG_EFFECT_SIZE="0.5794553826032444" ORDER="137591" O_E="3.1428571428571432" SE="0.6515616653388764" STUDY_ID="STD-Dixon-1975" TOTAL_1="34" TOTAL_2="43" VAR="2.3555316863587543" WEIGHT="43.307037787086344"/>
<DICH_DATA CI_END="157.20815150239417" CI_START="0.5291316028483362" EFFECT_SIZE="9.120515401296458" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1964750611736568" LOG_CI_START="-0.27643629907506934" LOG_EFFECT_SIZE="0.9600193810492936" ORDER="137592" O_E="1.0476190476190477" SE="1.452600374118757" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.473922902494331" WEIGHT="8.713190811801176"/>
<DICH_DATA CI_END="10.834601196580529" CI_START="0.5316713771569921" EFFECT_SIZE="2.400093193843265" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0348129303017097" LOG_CI_START="-0.2743567195567579" LOG_EFFECT_SIZE="0.3802281053724759" ORDER="137593" O_E="1.4804469273743015" SE="0.7690127328211467" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="1.6909584594737994" WEIGHT="31.088693191823165"/>
<DICH_DATA CI_END="39.860739942032886" CI_START="0.6674842393221734" EFFECT_SIZE="5.1581407191959" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.60054535632531" LOG_CI_START="-0.17555898442963458" LOG_EFFECT_SIZE="0.7124931859478377" ORDER="137594" O_E="1.5072463768115942" SE="1.0432924816177345" STUDY_ID="STD-Williams-1983" TOTAL_1="86" TOTAL_2="52" VAR="0.9187298871457108" WEIGHT="16.891078209289315"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5098903098242604" CI_END="5.986725351369708" CI_START="1.570487111565355" DF="2" EFFECT_SIZE="3.066280320650364" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="0.7771893347916544" LOG_CI_START="0.19603437664728096" LOG_EFFECT_SIZE="0.48661185571946775" NO="3" P_CHI2="0.47003650475370085" P_Z="0.0010299007514559015" STUDIES="3" TAU2="0.0" TOTAL_1="106" TOTAL_2="107" WEIGHT="100.0" Z="3.282228597707066">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="5.569862691706371" CI_START="0.9542639008174867" EFFECT_SIZE="2.3054541633278047" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.7458444890751178" LOG_CI_START="-0.020331504939925006" LOG_EFFECT_SIZE="0.3627564920675964" ORDER="137595" O_E="4.123809523809523" SE="0.45005557151677333" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="4.937052154195012" WEIGHT="57.53429738319675"/>
<DICH_DATA CI_END="11.665725978107524" CI_START="1.199959863810149" EFFECT_SIZE="3.741443966697406" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0669117708601967" LOG_CI_START="0.07916672003321817" LOG_EFFECT_SIZE="0.5730392454467075" ORDER="137596" O_E="3.9195402298850572" SE="0.5802063322726243" STUDY_ID="STD-Dixon-1975" TOTAL_1="44" TOTAL_2="43" VAR="2.9705377196459244" WEIGHT="34.61737798432845"/>
<DICH_DATA CI_END="112.35178503168254" CI_START="0.9465152277569737" EFFECT_SIZE="10.312258501325767" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.050579976828591" LOG_CI_START="-0.023872394613415546" LOG_EFFECT_SIZE="1.0133537911075876" ORDER="137597" O_E="1.5714285714285714" SE="1.2185435916898848" STUDY_ID="STD-Mery-1976" TOTAL_1="10" TOTAL_2="11" VAR="0.673469387755102" WEIGHT="7.8483246324747995"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.039264584366017" CI_END="2.621778470343829" CI_START="0.05173027755887072" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.36827344184553656" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="34.19460713331758" I2_Q="67.09420682001837" ID="CMP-003.09" LOG_CI_END="0.4185959927805421" LOG_CI_START="-1.2862551913770652" LOG_EFFECT_SIZE="-0.4338295992982616" METHOD="PETO" MODIFIED="2008-11-07 23:16:45 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.21879240215717266" P_Q="0.08128727399561009" P_Z="0.31852424225038234" Q="3.0389785607974766" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="194" TOTAL_2="195" WEIGHT="200.0" Z="0.9974951455627222">
<NAME>Adverse reactions: Miscellaneous</NAME>
<GROUP_LABEL_1>D-penicillamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Dose d-penicillamine: 125 to &lt; 500 mg/day</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8602356854066924E-4" CI_END="1.2953155333362236" CI_START="0.013895298927705317" DF="1" EFFECT_SIZE="0.13415959354964843" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.11237557358709853" LOG_CI_START="-1.8571321058670722" LOG_EFFECT_SIZE="-0.8723782661399868" NO="2" P_CHI2="0.9865066350468996" P_Z="0.08251046394995343" STUDIES="2" TAU2="0.0" TOTAL_1="142" TOTAL_2="142" WEIGHT="99.99999999999999" Z="1.7363019198825715">
<NAME>Dose d-penicillamine: 500 to &lt; 1000 mg/day</NAME>
<DICH_DATA CI_END="6.951612730514668" CI_START="0.002736055946476575" EFFECT_SIZE="0.13791302095497332" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8420855698725365" LOG_CI_START="-2.5628750264703264" LOG_EFFECT_SIZE="-0.8603947282988952" ORDER="137598" O_E="-0.49523809523809526" SE="2.000090709118581" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="0.24997732426303856" WEIGHT="33.45732200785345"/>
<DICH_DATA CI_END="2.1320225703497897" CI_START="0.008211096294467106" EFFECT_SIZE="0.13231115836209506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.32879179797483643" LOG_CI_START="-2.0855988547134143" LOG_EFFECT_SIZE="-0.8784035283692889" ORDER="137599" O_E="-1.005586592178771" SE="1.4182250208155596" STUDY_ID="STD-Shiokawa-1977" TOTAL_1="90" TOTAL_2="89" VAR="0.4971754938984427" WEIGHT="66.54267799214654"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="379.68293578402336" CI_START="0.14943780594501696" DF="0" EFFECT_SIZE="7.5325284518763835" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="2.579421078937613" LOG_CI_START="-0.82553951740525" LOG_EFFECT_SIZE="0.8769407807661815" NO="3" P_CHI2="1.0" P_Z="0.3127015560991342" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="1.0095695960312836">
<NAME>Dose d-penicillamine: 1000 or more mg/day</NAME>
<DICH_DATA CI_END="379.68293578402336" CI_START="0.14943780594501696" EFFECT_SIZE="7.5325284518763835" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.579421078937613" LOG_CI_START="-0.82553951740525" LOG_EFFECT_SIZE="0.8769407807661815" ORDER="137600" O_E="0.5047619047619047" SE="2.000090709118581" STUDY_ID="STD-Andrews-1973" TOTAL_1="52" TOTAL_2="53" VAR="0.24997732426303856" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>